Neoplastic Processes - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

RGD DISEASE ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.

Term:	Neoplastic Processes	go back to main search page
Accession:	DOID:9008192	browse the term
Definition:	The pathological mechanisms and forms taken by tissue during degeneration into a neoplasm and its subsequent activity.
Synonyms:	primary_id:	MESH:D009385

show annotations for term's descendants Sort by:
Rat (740) Mouse (746) Human (791) Chinchilla (631) Bonobo (669) Dog (724) Squirrel (641) Pig (711) Green Monkey (659) Naked Mole-rat (623) All
Genes (737) Strains (3)

Neoplastic Processes

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

chromatin assembly factor 1 subunit B

protein:increased expression::

RGD

NCBI chr11:33,200,894...33,221,076
Ensembl chr11:33,200,981...33,221,070

G

ETS transcription factor ERG

CTD Direct Evidence: marker/mechanism

NCBI chr11:34,678,614...34,900,951
Ensembl chr11:34,678,618...34,845,871

G

ETS variant transcription factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 6:55,590,149...55,681,784
Ensembl chr 6:55,590,234...55,681,775

G

ETS variant transcription factor 4

CTD Direct Evidence: marker/mechanism

NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974

G

ETS variant transcription factor 5

CTD Direct Evidence: marker/mechanism

NCBI chr11:78,608,618...78,666,221
Ensembl chr11:78,608,710...78,666,215

G

EWS RNA-binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:79,965,365...79,994,108
Ensembl chr14:79,965,368...79,994,544

G

high density lipoprotein binding protein

CTD Direct Evidence: marker/mechanism

NCBI chr 9:93,948,099...94,018,040
Ensembl chr 9:93,949,913...94,018,048

G

homeo box D9

CTD Direct Evidence: marker/mechanism

NCBI chr 3:59,600,575...59,602,755
Ensembl chr 3:59,600,575...59,602,754

G

HRas proto-oncogene, GTPase

CTD Direct Evidence: marker/mechanism

NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615

Anaplasia

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

carbonic anhydrase 9

CTD Direct Evidence: marker/mechanism

NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838

G

hypoxia inducible factor 1 subunit alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

Blast Crisis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

activation-induced cytidine deaminase

CTD Direct Evidence: marker/mechanism

NCBI chr 4:155,774,132...155,783,972
Ensembl chr 4:155,774,132...155,783,972

G

BCR activator of RhoGEF and GTPase

CTD Direct Evidence: marker/mechanism

NCBI chr20:13,469,325...13,596,942
Ensembl chr20:13,471,668...13,597,016

G

estrogen receptor 2

RGD

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

heme oxygenase 1

RGD

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

microRNA 150

miRNA:decreased expression:leukocytes

RGD

NCBI chr 1:95,605,024...95,605,108
Ensembl chr 1:95,605,024...95,605,108

G

transcobalamin 2

protein:increased expression::

RGD

NCBI chr14:78,813,343...78,828,549
Ensembl chr14:78,813,343...78,828,489

Bone Metastasis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arachidonate 12-lipoxygenase, 12S type

associated with Prostatic Neoplasms;

RGD

NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542

G

BRCA1 interacting helicase 1

associated with Breast Neoplasms; human gene in a mouse model

RGD

NCBI chr10:70,907,266...71,031,502
Ensembl chr10:70,907,371...71,030,324

G

C-X-C motif chemokine receptor 4

disease_progression

associated with hepatocellular carcinoma;protein:increased expression:liver (human)

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

ectonucleotide pyrophosphatase/phosphodiesterase 1

associated with Breast Neoplasms;mRNA:increased expression:bone element (human)

RGD

NCBI chr 1:20,698,746...20,763,741
Ensembl chr 1:20,698,764...20,763,715

G

microRNA 34a

susceptibility

associated with hepatocellular carcinoma;miRNA:decreased expression:serum, bone

RGD

NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103

G

matrix metallopeptidase 13

associated with Carcinoma, Renal Cell; mRNA, protein:increased expression:bone (human)

RGD

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

platelet derived growth factor D

associated with prostate carcinoma

RGD

NCBI chr 8:3,488,448...3,722,395
Ensembl chr 8:3,488,423...3,722,395

Carcinogenesis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ABL proto-oncogene 1, non-receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065

G

ADP-ribosylarginine hydrolase

RGD

NCBI chr11:62,299,831...62,306,170
Ensembl chr11:62,299,793...62,306,931

G

aldo-keto reductase family 1 member A1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674

G

AKT serine/threonine kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

B-Raf proto-oncogene, serine/threonine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463

G

caveolin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

cyclin-dependent kinase inhibitor 2A

CTD Direct Evidence: marker/mechanism

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

cut-like homeobox 1

CTD Direct Evidence: marker/mechanism

NCBI chr12:20,107,062...20,425,868
Ensembl chr12:20,107,311...20,425,866

G

DNA methyltransferase 1

disease_progression

RGD

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

DNA methyltransferase 3 alpha

disease_progression

RGD

NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687

G

endothelial PAS domain protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228

G

erb-b2 receptor tyrosine kinase 2

CTD Direct Evidence: marker/mechanism

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

GATA binding protein 3

CTD Direct Evidence: marker/mechanism

NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391

G

H19 imprinted maternally expressed transcript

CTD Direct Evidence: marker/mechanism

NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134

G

ISG15 ubiquitin-like modifier

CTD Direct Evidence: marker/mechanism

NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435

G

KRAS proto-oncogene, GTPase

CTD Direct Evidence: marker/mechanism

PMID:26595770 PMID:29247004

NCBI chr 4:178,185,418...178,218,484

G

mitogen-activated protein kinase kinase kinase 8

RGD

PMID:15287022 PMID:23533274

RGD:151356924, RGD:151356978

NCBI chr17:53,382,908...53,403,216
Ensembl chr17:53,383,131...53,403,216

G

MET proto-oncogene, receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

microRNA 143

CTD Direct Evidence: therapeutic

NCBI chr18:55,101,006...55,101,110
Ensembl chr18:55,101,006...55,101,110

G

NFE2 like bZIP transcription factor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

platelet-activating factor acetylhydrolase 1b, regulatory subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:59,533,042...59,591,808
Ensembl chr10:59,534,117...59,591,808

G

POU class 5 homeobox 1

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

secreted protein acidic and cysteine rich

CTD Direct Evidence: marker/mechanism

NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396

G

TNF superfamily member 8

CTD Direct Evidence: marker/mechanism

NCBI chr 5:77,250,942...77,277,364
Ensembl chr 5:77,251,373...77,277,421

Circulating Neoplastic Cells

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

erb-b2 receptor tyrosine kinase 2

CTD Direct Evidence: marker/mechanism

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

Liver Metastasis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

associated with colorectal cancer;mRNA:increased expression:liver (mouse)

RGD

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

B-Raf proto-oncogene, serine/threonine kinase

severity

associated with colorectal cancer;DNA:mutation:cds:
associated with colorectal cancer;DNA:mutations:multiple
associated with skin melanoma;DNA:missense mutations:cds:
associated with colorectal cancer;DNA:missense mutations:cds:pV599E,p.V600E (human)
associated with colorectal cancer;DNA:missense mutation:cds:p.V600E (human)

RGD

PMID:27737491 PMID:26775732 PMID:28787433 PMID:22331825 PMID:23010994

RGD:18337264, RGD:11554843, RGD:14696791, RGD:18337265, RGD:15039394

NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463

G

C-C motif chemokine ligand 2

disease_progression

associated with colorectal cancer

RGD

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

treatment

associated with Animal Mammary Neoplasms;

RGD

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cyclin D2

associated with colorectal cancer;protein:increased expression:colorectum

RGD

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin G1

treatment

human cells in mouse model

RGD

NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641

G

CD44 molecule

associated with Breast Neoplasm;protein:increased expression:liver

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

chromodomain helicase DNA binding protein 4

ameliorates

associated with human colon adenocarcinoma cells in a mouse model

RGD

NCBI chr 4:157,898,503...157,931,632
Ensembl chr 4:157,899,391...157,931,541

G

C-X-C motif chemokine ligand 10

treatment

associated with colon carcinoma;

RGD

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 12

ameliorates

associated with colorectal cancer; human cells in mouse model

RGD

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine receptor 4

ameliorates

associated with colorectal cancer; human cells in mouse model
human cells in mouse model; associated with colorectal cancer

RGD

PMID:30789971 PMID:29436696

RGD:151893289, RGD:152023643

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

death-domain associated protein

exacerbates

associated with colon cancer; mRNA:decreased expression:liver (human)
associated with pancreatic endocrine carcinoma;DNA:mutations:CDS:multiple (human)
associated with neuroendocrine tumor;DNA:mutations:CDS:multiple (human)

RGD

PMID:31942198 PMID:30339629 PMID:30342802

RGD:152025194, RGD:152025203, RGD:152025199

NCBI chr20:4,970,090...4,976,145
Ensembl chr20:4,970,092...4,975,843

G

discoidin domain receptor tyrosine kinase 1

treatment

mRNA:increased expression:liver (mouse)
human cells in mouse model; nilotinib

RGD

PMID:33110221 PMID:30666650 PMID:29438985

RGD:151347537, RGD:151347840, RGD:151347685

NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468

G

discoidin domain receptor tyrosine kinase 2

ameliorates

associated with colon carcinoma
associated with melanoma;

RGD

PMID:22071959 PMID:21701781

RGD:150429701, RGD:150429713

NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363

G

dedicator of cytokinesis 6

ameliorates

associated with stomach cancer;

RGD

NCBI chr 8:20,342,430...20,394,660
Ensembl chr 8:20,342,089...20,394,552

G

F-box and WD repeat domain containing 7

disease_progression

associated with colorectal cancer;

RGD

NCBI chr 2:170,149,706...170,311,536
Ensembl chr 2:170,149,694...170,309,941

G

Fibroblast growth factor receptor 1

associated with colorectal cancer;mRNA:increased expression:colorectal mucosa:

RGD

NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350

G

FOS like 2, AP-1 transcription factor subunit

human cells in mouse model

RGD

NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034

G

glypican 3

protein:increased expression:blood serum (human)

RGD

NCBI chr X:131,868,986...132,236,824
Ensembl chr X:131,868,990...132,236,798

G

hydroxymethylbilane synthase

associated with colon adenocarcinoma;protein:decreased activity:liver(rat)

RGD

NCBI chr 8:44,673,554...44,680,950
Ensembl chr 8:44,673,554...44,680,957

G

interleukin 2

treatment

associated with Colorectal Neoplasms, Carcinoma, Hepatocellular;
associated with colon carcinoma

RGD

PMID:11591892 PMID:9354462

RGD:8663446, RGD:14928215

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

IQ motif and Sec7 domain ArfGEF 1

human cells in mouse model

RGD

NCBI chr 4:123,168,719...123,488,300
Ensembl chr 4:123,168,719...123,488,172

G

mitogen activated protein kinase kinase 7

associated with colon cancer;protein:increased expression:colon (human)

RGD

NCBI chr12:2,591,312...2,600,534
Ensembl chr12:2,591,219...2,604,222

G

microRNA 141

associated with colorectal cancer;RNA:increased expression:liver:

RGD

NCBI chr 4:157,523,239...157,523,332
Ensembl chr 4:157,523,239...157,523,332

G

microRNA 148b

exacerbates

associated with stomach cancer;

RGD

NCBI chr 7:134,421,398...134,421,494
Ensembl chr 7:134,421,398...134,421,494

G

microRNA 155

RGD

NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718

G

microRNA 200b

associated with colorectal cancer;RNA:increased expression:liver:

RGD

NCBI chr 5:166,649,272...166,649,366
Ensembl chr 5:166,649,272...166,649,366

G

microRNA 200c

associated with colorectal cancer;RNA:increased expression:liver:

RGD

NCBI chr 4:157,523,679...157,523,747

G

microRNA 223

disease_progression

associated with colorectal cancer;

RGD

NCBI chr X:61,141,887...61,141,996
Ensembl chr X:61,141,887...61,141,996

G

microRNA 494

exacerbates

associated with pancreatic ductal adenocarcinoma;

RGD

NCBI chr 6:128,728,710...128,728,792
Ensembl chr 6:128,728,709...128,728,793

G

MPL proto-oncogene, thrombopoietin receptor

severity
exacerbates

associated with pancreatic ductal adenocarcinoma; human cells in mouse model
associated with colorectal carcinoma;protein:increased expression:colorectum (human)
associated with pancreatic cancer; protein:increased expression:liver, pancreas (human)

RGD

PMID:30770989 PMID:23747337 PMID:30770989

RGD:126925751, RGD:126925752, RGD:126925751

NCBI chr 5:131,973,895...131,987,472
Ensembl chr 5:131,973,895...131,986,797

G

NRAS proto-oncogene, GTPase

susceptibility

human gene in a mouse model;DNA:missense mutations:cds:p.G12V, p.Q61K (human)
associated with colorectal cancer;DNA:mutations:exons (human)
associated with melanoma;DNA:mutations: exons (human)

RGD

PMID:26799184 PMID:28011498 PMID:28787433

RGD:14696774, RGD:14696792, RGD:14696791

NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626

G

protein tyrosine phosphatase, receptor type, B

treatment

mouse tumor cells in mouse recipient

RGD

NCBI chr 7:51,953,375...52,034,751
Ensembl chr 7:51,930,015...52,034,748

G

RPTOR independent companion of MTOR, complex 2

disease_progression

mRNA:increased expression:liver (human)

RGD

PMID:30404068 PMID:30404068

RGD:152995463, RGD:152995463

NCBI chr 2:55,811,877...55,903,893
Ensembl chr 2:55,811,322...55,901,426

G

ring finger protein 43

associated with colorectal adenocarcinoma;mRNA:increased expression:liver (human)

RGD

NCBI chr10:72,461,508...72,537,301
Ensembl chr10:72,464,348...72,536,977

G

solute carrier family 3 member 2

severity

associated with colon adenocarcinoma

RGD

NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931

G

solute carrier family 7 member 5

severity

associated with colon cancer
associated with colon adenocarcinoma

RGD

PMID:11718450 PMID:11745822

RGD:151361129, RGD:151361130

NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823

G

SMAD family member 4

treatment

associated with colorectal carcinoma; DNA:mutations: :
associated with colorectal carcinoma;protein:decreased expression:colorectum:

RGD

PMID:29551247 PMID:17390050

RGD:18937000, RGD:21066338

NCBI chr18:67,243,742...67,274,438
Ensembl chr18:67,243,742...67,274,438

G

SRY-box transcription factor 30

ameliorates

RGD

NCBI chr10:30,417,499...30,446,441
Ensembl chr10:30,418,473...30,446,453

G

SRC proto-oncogene, non-receptor tyrosine kinase

disease_progression

associated with colon cancer;protein:increased activity:colon

RGD

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

vascular endothelial growth factor A

associated with colorectal carcinoma;mRNA,protein:increased expression:liver:

RGD

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

lung metastasis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ADAM metallopeptidase domain 28

ameliorates

associated with lung carcinoma, breast carcinoma
associated with lung adenocarcinoma;

RGD

PMID:22636800 PMID:26800504

RGD:153297785, RGD:11531771

NCBI chr15:43,774,463...43,840,726
Ensembl chr15:42,944,467...43,840,672

G

Rho GTPase activating protein 5

associated with Mammary Neoplasms, Experimental

RGD

NCBI chr 6:69,975,904...70,039,299
Ensembl chr 6:69,976,214...70,037,660

G

AT-rich interaction domain 2

exacerbates

associated with hepatocellular carcinoma,

RGD

NCBI chr 7:127,447,192...127,565,987
Ensembl chr 7:127,447,278...127,563,512

G

alpha-2-glycoprotein 1, zinc-binding

ameliorates

associated with hepatocellular carcinoma;

RGD

PMID:27993894 PMID:26902423

RGD:153350132, RGD:153350133

NCBI chr12:16,930,990...16,939,333
Ensembl chr12:16,931,024...16,939,091

G

carbonic anhydrase 12

ameliorates

associated with breast cancer;

RGD

NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440

G

Cbl proto-oncogene B

severity

associated with stomach carcinoma;

RGD

NCBI chr11:48,589,878...48,756,940
Ensembl chr11:48,592,703...48,756,839

G

cyclin G1

RGD

NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641

G

chromodomain helicase DNA binding protein 4

ameliorates

associated with human colon adenocarcinoma cells in a mouse model

RGD

NCBI chr 4:157,898,503...157,931,632
Ensembl chr 4:157,899,391...157,931,541

G

collagen type X alpha 1 chain

ameliorates

associated with H1299 cell

RGD

NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494

G

C-X-C motif chemokine receptor 4

ameliorates

associated with colorectal cancer; human cells in mouse model
associated with nasopharynx carcinoma; human cells in mouse model
associated with osteosarcoma and melanoma

RGD

PMID:31938138 PMID:16000558 PMID:26498029 PMID:18071913

RGD:151665329, RGD:151893515, RGD:152023752, RGD:152177473

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

discoidin domain receptor tyrosine kinase 1

RGD

NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468

G

discoidin domain receptor tyrosine kinase 2

exacerbates

associated with tongue squamous cell carcinoma;

RGD

NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363

G

fatty acid synthase

associated with head and neck squamous cell carcinoma

RGD

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

FOS like 2, AP-1 transcription factor subunit

human cells in mouse model

RGD

NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034

G

hypoxia inducible lipid droplet-associated

human cells in mouse model

RGD

NCBI chr 4:57,871,088...57,874,048
Ensembl chr 4:57,871,110...57,874,557

G

IQ motif and Sec7 domain ArfGEF 1

human cells in mouse model

RGD

NCBI chr 4:123,168,719...123,488,300
Ensembl chr 4:123,168,719...123,488,172

G

integrin subunit alpha V

treatment

human cells in rat model

RGD

NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639

G

mitogen-activated protein kinase kinase kinase 1

ameliorates

associated with breast carcinoma

RGD

NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463

G

mitogen-activated protein kinase kinase kinase 8

ameliorates

associated with clear cell renal cell carcinoma

RGD

NCBI chr17:53,382,908...53,403,216
Ensembl chr17:53,383,131...53,403,216

G

microRNA 423

human cells in mouse model

RGD

NCBI chr10:61,914,142...61,914,220
Ensembl chr10:61,914,133...61,914,226

G

microRNA 494

ameliorates

associated with hepatocellular carcinoma

RGD

PMID:25820676 PMID:28055013

RGD:155900754, RGD:156430322

NCBI chr 6:128,728,710...128,728,792
Ensembl chr 6:128,728,709...128,728,793

G

NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor

associated with hepatocellular carcinoma

RGD

NCBI chr14:79,627,399...79,710,709
Ensembl chr14:79,627,399...79,710,667

G

neurotrophic receptor tyrosine kinase 3

ameliorates

associated with mammary carcinoma

RGD

NCBI chr 1:132,116,472...132,503,849
Ensembl chr 1:132,132,849...132,503,286

G

Paxip1-associated glutamate-rich protein 1

human cells in mouse model

RGD

NCBI chr 1:181,622,698...181,625,024

G

protein tyrosine phosphatase, receptor type, B

treatment

RGD

NCBI chr 7:51,953,375...52,034,751
Ensembl chr 7:51,930,015...52,034,748

G

RPTOR independent companion of MTOR, complex 2

human cells in mouse model

RGD

PMID:20978191 PMID:29809146

RGD:152995469, RGD:152995516

NCBI chr 2:55,811,877...55,903,893
Ensembl chr 2:55,811,322...55,901,426

G

regulatory associated protein of MTOR, complex 1

RGD

NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983

G

splicing factor 3B subunit 4

human cells in mouse model

RGD

NCBI chr 2:183,732,791...183,737,545
Ensembl chr 2:183,732,754...183,737,959

G

SRY-box transcription factor 30

ameliorates

RGD

NCBI chr10:30,417,499...30,446,441
Ensembl chr10:30,418,473...30,446,453

G

SRC proto-oncogene, non-receptor tyrosine kinase

treatment
ameliorates

associated with breast cancer;
associated with nasopharynx carcinoma;

RGD

PMID:15753384 PMID:27078847

RGD:1581400, RGD:150521726

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

Lymphatic Metastasis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 13

susceptibility

DNA:amplification:cds: (human, male)

RGD

NCBI chr14:83,873,397...84,376,138
Ensembl chr14:83,873,940...84,375,075

G

ADAM metallopeptidase domain 28

associated with breast cancer;DNA:hypermethylation:

RGD

NCBI chr15:43,774,463...43,840,726
Ensembl chr15:42,944,467...43,840,672

G

adhesion G protein-coupled receptor B1

disease_progression

associated with stomach cancer;

RGD

NCBI chr 7:106,404,827...106,476,902
Ensembl chr 7:106,404,958...106,476,902

G

activation-induced cytidine deaminase

associated with stomach cancer;protein:increased expression:stomach (human)

RGD

NCBI chr 4:155,774,132...155,783,972
Ensembl chr 4:155,774,132...155,783,972

G

angiopoietin-like 4

CTD Direct Evidence: therapeutic

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

annexin A1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

aquaporin 3 (Gill blood group)

CTD Direct Evidence: marker/mechanism

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

Rho GTPase activating protein 5

associated with nasopharynx carcinoma;mRNA, protein:increased expression: epithelium of nasopharynx

RGD

NCBI chr 6:69,975,904...70,039,299
Ensembl chr 6:69,976,214...70,037,660

G

ASXL transcriptional regulator 1

associated with colorectal cancer

RGD

NCBI chr 3:141,814,012...141,881,526
Ensembl chr 3:141,813,433...141,881,538

G

Axl receptor tyrosine kinase

associated Pancreatic Neoplasms

RGD

NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265

G

BAG cochaperone 1

disease_progression

associated with Breast Neoplasms:protein:increased expression:breast

RGD

NCBI chr 5:56,068,494...56,081,075
Ensembl chr 5:56,068,494...56,081,075

G

BMP and activin membrane-bound inhibitor

associated with stomach cancer; protein:increased expression: :

RGD

NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060

G

BarH-like homeobox 2

associated with oral squamous cell carcinoma; mRNA:decreased expression:mouth mucosa

RGD

NCBI chr14:3,340,465...3,345,362
Ensembl chr14:3,340,465...3,345,353

G

BCL2, apoptosis regulator

associated with Breast Neoplasms;protein:increased expression:lymph node

RGD

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BCL2-interacting killer

associated with cholangiocarcinoma;DNA:CNV::

RGD

NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296

G

baculoviral IAP repeat-containing 5

disease_progression

associated with Cervix Neoplasms;mRNA:splice variant
associated with Breast Neoplasms

RGD

PMID:17877643 PMID:17285241

RGD:2293098, RGD:2293103

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

B-Raf proto-oncogene, serine/threonine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463

G

bromodomain containing 7

severity

protein:increased expression:lung:

RGD

NCBI chr19:18,708,792...18,737,497
Ensembl chr19:18,709,022...18,737,494

G

basigin

disease_progression

associated with Breast Neoplasms

RGD

NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387

G

Bruton tyrosine kinase

disease_progression

associated with lung adenocarcinoma;protein:increased expression:lung (human)

RGD

NCBI chr X:97,722,796...97,762,315
Ensembl chr X:97,722,802...97,761,853

G

calcium binding protein 39

associated with pancreatic cancer;RNA:increased expression:pancreas

RGD

NCBI chr 9:86,463,095...86,524,545
Ensembl chr 9:86,463,095...86,524,544

G

carbonic anhydrase 9

associated with Cervix Neoplasms

RGD

NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838

G

caspase 9

associated with Carcinoma, Non-Small-Cell Lung;DNA:SNP:exon:rs1052576 (human)

RGD

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

caveolin 1

disease_progression

associated with Melanoma

RGD

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

Cbl proto-oncogene

associated with stomach carcinoma;protein:increased expression:stomach

RGD

NCBI chr 8:44,487,824...44,571,620
Ensembl chr 8:44,489,410...44,571,176

G

Cbl proto-oncogene B

associated with stomach carcinoma;

RGD

NCBI chr11:48,589,878...48,756,940
Ensembl chr11:48,592,703...48,756,839

G

cyclin D2

associated with colorectal cancer;protein:increased expression:colorectum

RGD

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin E1

associated with Carcinoma, Transitional Cell;protein:decreased expression

RGD

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cyclin H

CTD Direct Evidence: marker/mechanism

NCBI chr 2:15,835,064...15,855,648
Ensembl chr 2:15,834,833...15,855,819

G

C-C motif chemokine receptor 5

associated with Breast Neoplasms;mRNA:increased expression:lymph node

RGD

NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260

G

CD274 molecule

CTD Direct Evidence: marker/mechanism

NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450

G

CD40 molecule

associated with breast cancer;DNA:snps:5' utr, intron:c.-1T>C, c.51+914T>G (rs1883832, rs4810485) (human)

RGD

NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534

G

CD44 molecule

associated with Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms;mRNA, protein:splice variant, increased expression:breast, large intestine, stomach

RGD

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

cadherin 1

associated with Cervix Neoplasms
associated with Breast Neoplasms

RGD

PMID:18097581 PMID:17649807

RGD:2296046, RGD:2289498

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cyclin-dependent kinase inhibitor 1A

associated with Eyelid Neoplasms;
associated with Oral Squamous Cell Carcinoma;

RGD

PMID:19628749 PMID:15817070

RGD:8661799, RGD:8662374

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

associated with Breast Neoplasms
associated with non-small cell lung carcinoma

RGD

PMID:12015771 PMID:28601655

RGD:2293607, RGD:13673921

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 2A

CTD Direct Evidence: marker/mechanism

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

claudin 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

CLPTM1-like

associated with esophagus squamous cell carcinoma; mRNA:increased expression:esophagus

RGD

NCBI chr 1:29,667,545...29,683,530
Ensembl chr 1:29,667,545...29,683,530

G

clusterin

associated with breast cancer;DNA:snp:promoter:g.27611345C>G (rs9331888) (human)

RGD

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

catechol-O-methyltransferase

associated with breast cancer;DNA:missense mutation:cds:p.V108/158M (human)

RGD

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

C-reactive protein

susceptibility

associated with Breast Neoplasm; DNA:polymorphism: :1846C>T(rs1205)(human)

RGD

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

colony stimulating factor 1 receptor

associated with Breast Neoplasms

RGD

NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415

G

cytotoxic T-lymphocyte-associated protein 4

associated with Prostatic Neoplasms

RGD

NCBI chr 9:62,318,874...62,325,978
Ensembl chr 9:62,319,312...62,324,963

G

catenin alpha 1

associated with Breast Neoplasms

RGD

NCBI chr18:26,728,246...26,860,911
Ensembl chr18:26,728,485...26,860,910

G

catenin beta 1

associated with Breast Neoplasms;protein:decreased expression

RGD

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

C-X-C motif chemokine ligand 12

disease_progression

associated with stomach cancer;mRNA:increased expression:stomach (human)

RGD

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine receptor 4

associated with nasopharynx carcinoma; protein:increased expression:lymph node (human)

RGD

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

cytochrome c, somatic

associated with non-small cell lung carcinoma; protein:decreased expression:serum

RGD

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

discoidin domain receptor tyrosine kinase 1

severity

mRNA, protein:increased expression:mouth (human)
mRNA:increased expression:kidney, lymph nodes (human)

RGD

PMID:31253192 PMID:27020590

RGD:151347620, RGD:151347863

NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468

G

discoidin domain receptor tyrosine kinase 2

disease_progression

associated with oral squamous cell carcinoma

RGD

NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363

G

DNA methyltransferase 3 beta

associated with Carcinoma, Pancreatic Ductal;

RGD

NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124

G

estrogen receptor binding site associated antigen 9

associated with Prostatic Neoplasm;protein:increased expression:prostate gland, lymph node
associated with Breast Neoplasms;protein:increased expression:breast

RGD

PMID:12845666 PMID:12054692 PMID:17187007

RGD:2289856, RGD:2298489, RGD:2289847

NCBI chr 7:75,810,950...75,828,902
Ensembl chr 7:75,810,594...75,861,248

G

epidermal growth factor receptor

treatment

associated with Squamous Cell Carcinoma of the Tongue

RGD

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

euchromatic histone lysine methyltransferase 2

associated with Melanoma;
associated with Esophageal Squamous Cell Carcinoma;

RGD

PMID:24658378 PMID:24805087

RGD:9590069, RGD:9590071

NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547

G

Eph receptor A2

protein:increased expression:esophagus (human)

RGD

NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117

G

erb-b2 receptor tyrosine kinase 2

disease_progression

associated with Breast Neoplasms;DNA, protein:polymorphism, increased expression:serum:p.I655V
associated with lung adenocarcinoma; protein:increased expression:lung (human)
CTD Direct Evidence: marker/mechanism
associated with Carcinoma, Transitional Cell;protein:increased expression:urinary bladder

PMID:21532492 PMID:21966491 PMID:18237248 PMID:18097576

RGD:153344600, RGD:2289925, RGD:2289926

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

erb-b2 receptor tyrosine kinase 3

associated with Prostatic Neoplasms;protein:increased expression, altered localization:lymph node, nucleus
associated with head and neck squamous cell carcinoma

RGD

PMID:17634423 PMID:20604875

RGD:2289944, RGD:126790467

NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525

G

erb-b2 receptor tyrosine kinase 4

disease_progression
severity

associated with oral squamous cell carcinoma
associated with lung non-small cell carcinoma
associated with colorectal adenocarcinoma

RGD

PMID:27444519 PMID:21324275 PMID:16507107

RGD:126781762, RGD:126790471, RGD:126781766

NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595

G

Fas cell surface death receptor

susceptibility

associated with Cervix Neoplasms;DNA:polymorphism:promoter:-1377G>A

RGD

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

fibroblast growth factor 1

associated with Cervix Neoplasms;mRNA:increased expression:lymph node

RGD

NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357

G

fibroblast growth factor receptor 2

associated with breast cancer;DNA:snp:intron:c.109+7033T>A (rs1219648) (human)

RGD

NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626

G

Fms related receptor tyrosine kinase 3

disease_progression

associated with Prostatic Neoplasms

RGD

NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474

G

forkhead box A1

associated with lung non-small cell carcinoma; mRNA:increased expression: :

RGD

NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188

G

forkhead box P1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:131,559,599...132,155,092
Ensembl chr 4:131,564,756...132,112,258

G

glutathione peroxidase 3

associated with stomach carcinoma; DNA:hypermethylation:promoter

RGD

NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035

G

glutamate ionotropic receptor kainate type subunit 2

CTD Direct Evidence: marker/mechanism

NCBI chr20:52,135,325...52,833,061
Ensembl chr20:52,133,851...52,838,375

G

high mobility group box 1

associated with Adenocarcinoma, Colon

RGD

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

intercellular adhesion molecule 1

associated with Breast Neoplasms

RGD

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

immediate early response 2

RGD

NCBI chr19:23,494,551...23,496,075
Ensembl chr19:23,494,184...23,499,211

G

interleukin 13

associated with Melanoma, Cutaneous Malignant;mRNA:increased expression:lymph node

RGD

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 18

associated with Breast Neoplasms;protein:increased expression:serum

RGD

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

inhibitor of growth family, member 4

CTD Direct Evidence: therapeutic

NCBI chr 4:157,841,882...157,850,519
Ensembl chr 4:157,841,951...157,850,265

G

IQ motif and Sec7 domain ArfGEF 1

disease_progression

associated with lung adenocarcinoma; protein:increased expression:lung (human)

RGD

NCBI chr 4:123,168,719...123,488,300
Ensembl chr 4:123,168,719...123,488,172

G

integrin subunit beta 1

associated with non-small cell lung carcinoma,

RGD

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

potassium inwardly-rectifying channel, subfamily J, member 12

CTD Direct Evidence: marker/mechanism

NCBI chr10:45,696,621...45,745,528
Ensembl chr10:45,696,849...45,745,492

G

kinase insert domain receptor

treatment

associated with Squamous Cell Carcinoma of the Tongue

RGD

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

KiSS-1 metastasis-suppressor

CTD Direct Evidence: therapeutic

NCBI chr13:44,775,106...44,780,707
Ensembl chr13:44,774,823...44,780,612

G

KLF transcription factor 7

CTD Direct Evidence: therapeutic

NCBI chr 9:65,433,683...65,526,372
Ensembl chr 9:65,437,167...65,526,261

G

lysine methyltransferase 2D

associated with stomach cancer

RGD

NCBI chr 7:129,980,744...130,022,088
Ensembl chr 7:129,962,887...130,020,325

G

laminin subunit gamma 2

associated with lung squamous cell carcinoma;

RGD

NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200

G

leucine rich repeat containing 59

CTD Direct Evidence: marker/mechanism

NCBI chr10:79,572,295...79,586,953
Ensembl chr10:79,572,317...79,602,533

G

macrophage immunometabolism regulator

CTD Direct Evidence: marker/mechanism

NCBI chr 9:98,420,760...98,440,818
Ensembl chr 9:98,420,376...98,441,733

G

MET proto-oncogene, receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

microRNA 125a

associated with stomach cancer;

RGD

NCBI chr 1:58,677,626...58,677,710
Ensembl chr 1:58,677,626...58,677,710

G

microRNA 152

associated with breast cancer

RGD

NCBI chr10:81,832,936...81,833,020
Ensembl chr10:81,832,936...81,833,020

G

microRNA 155

disease_progression

associated with colon cancer

RGD

PMID:26885061 PMID:29893326 PMID:27856635

RGD:21079444, RGD:21409756, RGD:21079446

NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718

G

microRNA 187

associated with oral squamous cell carcinoma; RNA:increased expression:plasma

RGD

NCBI chr18:15,731,194...15,731,297
Ensembl chr18:15,731,194...15,731,297

G

microRNA 224

associated with colorectal cancer; mRNA:decreased expression:colorectal mucosa:

RGD

NCBI chr X:150,065,088...150,065,169
Ensembl chr X:150,065,088...150,065,169

G

microRNA 30a

associated with Colorectal Neoplasms

RGD

NCBI chr 9:25,737,600...25,737,670
Ensembl chr 9:25,737,600...25,737,670

G

matrix metallopeptidase 2

disease_progression

associated with Tongue Neoplasms
associated with Carcinoma, Ductal, Breast

RGD

PMID:23107277 PMID:23280016

RGD:8547824, RGD:8655998

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 3

susceptibility

associated with breast cancer;DNA:deletion:promoter:-1170_-1172delA (human)

PMID:15161710 PMID:15161710

RGD:8662937, RGD:8662937

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 9

disease_progression

associated with Carcinoma, Non-Small-Cell Lung;protein:increased expression:serum
associated with Tongue Neoplasms
associated with Endometrial Neoplasms;protein:increased expression:endometrium

RGD

PMID:20704821 PMID:23107277 PMID:12487935

RGD:5129215, RGD:8547824, RGD:2298523

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

mutS homolog 2

associated with laryngeal squamous cell carcinoma

RGD

NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938

G

mesothelin

CTD Direct Evidence: marker/mechanism

NCBI chr10:14,771,946...14,781,382
Ensembl chr10:14,771,961...14,777,643

G

metallothionein 1

CTD Direct Evidence: marker/mechanism

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049

G

metastasis associated 1

associated with Carcinoma, Non-Small-Cell Lung;mRNA:increased expression:lung

RGD

NCBI chr 6:132,178,608...132,217,641
Ensembl chr 6:132,178,853...132,217,641

G

mechanistic target of rapamycin kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

mucin 1, cell surface associated

associated with Common Bile Duct Neoplasms
associated with Esophageal Neoplasms
associated with Carcinoma, Renal Cell;
associated with Gallbladder Neoplasms;protein:altered localization:gallbladder

RGD

PMID:16222735 PMID:21339746 PMID:10390012 PMID:11295067

RGD:2324649, RGD:7349383, RGD:7245968, RGD:2324860

NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733

G

mucin 5AC, oligomeric mucus/gel-forming

associated with chloangiocarcinoma;protein:increased expression:bile duct

RGD

NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475

G

neural cell adhesion molecule 1

RGD

NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014

G

NME/NM23 nucleoside diphosphate kinase 1

associated with Cervix Neoplasms; associated with Endometrial Neoplasms
associated with Breast Neoplasms

RGD

PMID:8855975 PMID:8102131 PMID:9036878

RGD:2299062, RGD:2299077, RGD:2299061

NCBI chr10:78,907,036...78,929,659
Ensembl chr10:78,906,083...78,916,408

G

NME/NM23 nucleoside diphosphate kinase 2

associated with Cervix Neoplasms; associated with Endometrial Neoplasms

RGD

NCBI chr10:78,898,097...78,903,514
Ensembl chr10:78,897,770...78,903,538

G

nitric oxide synthase 3

susceptibility

associated with Breast Neoplasms;DNA:polymorphisms:promoter, exon:-786T>C,p.E298D (human)

RGD

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

8-oxoguanine DNA glycosylase

associated with breast cancer;DNA:missense mutation:cds:p.S326C (rs1052133) (human)

RGD

NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766

G

Paxip1-associated glutamate-rich protein 1

disease_progression

protein:decreased expression:esophagus (human)

RGD

NCBI chr 1:181,622,698...181,625,024

G

platelet derived growth factor subunit A

associated with Breast Neoplasms;mRNA:increased expression:breast

RGD

NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497

G

platelet derived growth factor subunit B

associated with Breast Neoplasms;mRNA:increased expression:lymph node

RGD

NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984

G

3-phosphoinositide dependent protein kinase-1

associated with non-small cell lung carcinoma;mRNA:increased expression:blood serum

RGD

NCBI chr10:13,105,435...13,182,664
Ensembl chr10:13,105,498...13,174,623

G

podoplanin

associated with Breast Neoplasms
associated with Cervix Neoplasms

RGD

PMID:18165897 PMID:16528371

RGD:2292231, RGD:2292237

NCBI chr 5:155,601,691...155,635,656
Ensembl chr 5:155,601,691...155,635,656

G

phosphatidylethanolamine binding protein 1

associated with Breast Neoplasms
associated with Cervix Neoplasms

RGD

PMID:16243812 PMID:18191186

RGD:2302868, RGD:2302867

NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha

associated with Colorectal Neoplasms

RGD

NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta

associated with Colorectal Neoplasms

RGD

NCBI chr 8:99,594,600...99,699,772
Ensembl chr 8:99,594,644...99,699,663

G

phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 2:182,628,299...182,671,584
Ensembl chr 2:182,628,300...182,671,598

G

POU class 5 homeobox 1

associated with Seminoma; associated with Carcinoma, Embryonal

RGD

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

peroxisome proliferator-activated receptor gamma

associated with Cholangiocarcinoma;protein:increased expression:bile duct epithelium

RGD

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1

associated with Prostatic Neoplasms

RGD

NCBI chr 3:155,306,950...155,456,688
Ensembl chr 3:155,306,950...155,456,688

G

phosphatase and tensin homolog

associated with Prostatic Neoplasms;protein:decreased expression:prostate
associated with Breast Neoplasms

RGD

PMID:17163422 PMID:17919877

RGD:2292507, RGD:2292499

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin-endoperoxide synthase 2

associated with Biliary Tract Neoplasms
associated with carcinoma, non-small-cell lung; DNA:SNP: :929G>C(human)
associated with Breast Neoplasms

RGD

PMID:18159174 PMID:20016751 PMID:18353210

RGD:2317165, RGD:5135471, RGD:2300128

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine kinase 2

associated with lung squamous cell carcinoma; protein:increased tyrosine phosphorylation:lymph node

RGD

NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783

G

protein tyrosine phosphatase, non-receptor type 13

associated with lung squamous cell carcinoma; protein:decreased expression:lymph node

RGD

NCBI chr14:6,108,202...6,282,619
Ensembl chr14:6,108,211...6,282,563

G

receptor activity modifying protein 2

disease_progression

associated with colorectal cancer; protein:increased expression:lymph node (human)

NCBI chr10:86,187,366...86,190,692
Ensembl chr10:86,188,812...86,231,829

G

receptor activity modifying protein 3

associated with colorectal cancer; protein:increased expression:lymph node (human)

NCBI chr14:81,527,404...81,544,905
Ensembl chr14:81,527,385...81,544,902

G

Ras association domain family member 2

CTD Direct Evidence: marker/mechanism

NCBI chr 3:119,244,288...119,280,462
Ensembl chr 3:119,245,821...119,280,431

G

RNA binding motif protein 10

associated with lung adenocarcinoma;DNA:missense mutation:exon:p.R241C (c.763C>T) (human)

RGD

NCBI chr X:1,540,399...1,572,571
Ensembl chr X:1,540,398...1,572,575

G

RELA proto-oncogene, NF-kB subunit

associated with Prostatic Neoplasms;protein:altered localization:nucleus, prostate gland

RGD

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ret proto-oncogene

associated with Pancreatic Neoplasms

RGD

NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176

G

ras homolog family member A

associated with Bladder Neoplasms;protein:increased expression:lymph node
associated with colorectal cancer

RGD

PMID:12855641 PMID:17597401

RGD:2298872, RGD:13432052

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

RPTOR independent companion of MTOR, complex 2

associated with breast ductal carcinoma; protein:increased expression:breast tumor, lymph node (human)

RGD

NCBI chr 2:55,811,877...55,903,893
Ensembl chr 2:55,811,322...55,901,426

G

RUNX family transcription factor 1

associated with Carcinoid Tumor

RGD

NCBI chr11:31,839,880...32,074,427
Ensembl chr11:31,843,764...32,074,542

G

stratifin

CTD Direct Evidence: marker/mechanism

NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314

G

S-phase kinase associated protein 2

associated with Endometrial Neoplasms;protein:increased expression:endometrium

RGD

NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338

G

solute carrier family 22 member 22

CTD Direct Evidence: marker/mechanism

NCBI chr 7:88,720,425...88,750,111
Ensembl chr 7:88,720,427...88,750,111

G

solute carrier family 7 member 5

severity

associated with stomach carcinoma
associated with gastric adenocarcinoma;protein:increased expression: :

RGD

PMID:25908107 PMID:21501294

RGD:11052781, RGD:151361203

NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823

G

SMAD family member 4

associated with Breast Neoplasms

RGD

NCBI chr18:67,243,742...67,274,438
Ensembl chr18:67,243,742...67,274,438

G

smoothened, frizzled class receptor

associated with colorectal cancer

RGD

NCBI chr 4:58,343,626...58,373,823
Ensembl chr 4:58,343,529...58,373,829

G

synuclein, gamma

RGD

NCBI chr16:9,700,513...9,705,751
Ensembl chr16:9,700,514...9,705,368

G

suppressor of cytokine signaling 2

associated with Prostatic Neoplasms

RGD

NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548

G

suppressor of cytokine signaling 3

associated with Breast Neoplasms

RGD

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

superoxide dismutase 2

disease_progression

associated with tongue neoplasms;
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:10853026 PMID:19381893 PMID:20618948 PMID:20618948

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

SRY-box transcription factor 2

disease_progression

associated with Breast Neoplasms

RGD

NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338

G

SRC proto-oncogene, non-receptor tyrosine kinase

associated with colon adenocarcinoma,

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

ST14 transmembrane serine protease matriptase

associated with Endometrial Neoplasms

RGD

NCBI chr 8:29,540,805...29,581,704
Ensembl chr 8:29,540,811...29,581,517

G

signal transducer and activator of transcription 3

CTD Direct Evidence: marker/mechanism

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

serine/threonine kinase 11

associated with Breast Neoplasms;protein:decreased expression

RGD

NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315

G

telomerase reverse transcriptase

disease_progression

associated with lung non-small cell carcinoma;

RGD

NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561

G

TIMP metallopeptidase inhibitor 1

associated with Endometrial Neoplasms;protein:increased expression:endometrium

RGD

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

TIMP metallopeptidase inhibitor 3

associated with Breast Neoplasms;mRNA:increased expression:breast

RGD

NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839

G

TIMP metallopeptidase inhibitor 4

associated with Breast Neoplasms;mRNA:increased expression:breast

RGD

NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558

G

toll-like receptor 4

associated with Carcinoma, Ductal, Breast;

RGD

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor protein p53

associated with Penile Neoplasms
associated with Carcinoma, Squamous Cell;
associated with Breast Neoplasms;DNA:missense mutation, duplication:cds, intron:p.R72P

RGD

PMID:18268397 PMID:18059331 PMID:18230179

RGD:2290533, RGD:8547790, RGD:2290534

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tumor protein p53 binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822

G

tRNA methyltransferase 11 homolog

CTD Direct Evidence: marker/mechanism

NCBI chr 1:27,054,437...27,109,765
Ensembl chr 1:27,054,420...27,201,610

G

TSC complex subunit 2

associated with Breast Neoplasms

RGD

NCBI chr10:13,621,135...13,655,773
Ensembl chr10:13,621,136...13,655,951

G

thyroid stimulating hormone receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 6:110,341,585...110,475,297
Ensembl chr 6:110,341,581...110,474,538

G

transthyretin

associated with colorectal cancer;protein:decreased expresion:blood serum (human)

RGD

NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008

G

thymidine phosphorylase

associated with Cholangiocarcinoma
associated with Breast Neoplasms

RGD

PMID:11927969 PMID:10685502

RGD:2325027, RGD:2293725

NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874
Ensembl chr 7:120,438,770...120,443,874

G

vascular endothelial growth factor A

associated with Cervix Neoplasms
associated with Breast neoplasms;

RGD

PMID:19783962 PMID:17597103

RGD:2315454, RGD:7421574

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vascular endothelial growth factor C

exacerbates
disease_progression

associated with Carcinoma, Transitional Cell;protein:increased expression:urinary bladder
associated with pancreatic adenocarcinoma;protein:increased expression:pancreas (human)
associated with Lymphatic Metastasis;
associated with thyroid diseases;mRNA:increased expression:thyroid gland:
associated with Breast Neoplasms
associated with Prostatic Neoplasms
associated with Cervix Neoplasms

RGD

PMID:17034609 PMID:18061373 PMID:15289890 PMID:12203051 PMID:19923084 More...

RGD:2315484, RGD:155630642, RGD:7488946, RGD:7483611, RGD:2315469, RGD:2315474, RGD:2315475

NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848

G

vascular endothelial growth factor D

associated with Breast Neoplasms
associated with Cervix Neoplasms

RGD

PMID:17951197 PMID:19589137

RGD:2315480, RGD:2315475

NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295

G

WD repeat containing, antisense to TP53

associated with lung non-small cell carcinoma;
associated with esophagus squamous cell carcinoma;

RGD

PMID:31281482 PMID:24626331

RGD:21081513, RGD:21081532

NCBI chr10:54,282,092...54,299,908
Ensembl chr10:54,282,105...54,298,929

Neoplasm Invasiveness

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aconitase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391

G

actin, beta

CTD Direct Evidence: marker/mechanism

NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103

G

AHNAK nucleoprotein

CTD Direct Evidence: marker/mechanism

NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926

G

aryl hydrocarbon receptor

CTD Direct Evidence: therapeutic

PMID:25826687 PMID:27752740

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aldo-keto reductase family 1 member B10

CTD Direct Evidence: marker/mechanism

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

aldolase, fructose-bisphosphate A

CTD Direct Evidence: marker/mechanism

NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182

G

alkB homolog 8, tRNA methyltransferase

CTD Direct Evidence: marker/mechanism

NCBI chr 6:378,779...449,382
Ensembl chr 6:378,100...452,165

G

arachidonate 5-lipoxygenase

CTD Direct Evidence: marker/mechanism

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

alpha-1-microglobulin/bikunin precursor

CTD Direct Evidence: therapeutic

NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331

G

angiomotin-like 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:11,348,651...11,467,564
Ensembl chr 8:11,353,674...11,467,573

G

angiopoietin 1

associated with Mammary Neoplasms, Animal;mRNA:increased expression:mammary gland

RGD

NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067

G

angiopoietin-like 4

CTD Direct Evidence: therapeutic

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

annexin A1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

annexin A2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658

G

ADP-ribosylation factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:43,997,983...44,014,461
Ensembl chr10:43,997,986...44,014,434

G

Axl receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265

G

BCAR1 scaffold protein, Cas family member

CTD Direct Evidence: marker/mechanism

NCBI chr19:39,679,215...39,713,907
Ensembl chr19:39,679,204...39,713,907

G

BRMS1, transcriptional repressor and anoikis regulator

CTD Direct Evidence: therapeutic

NCBI chr 1:202,345,766...202,355,028
Ensembl chr 1:202,345,704...202,355,028

G

basigin

CTD Direct Evidence: marker/mechanism

NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387

G

calreticulin

CTD Direct Evidence: marker/mechanism

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

calumenin

CTD Direct Evidence: marker/mechanism

NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593

G

catalase

CTD Direct Evidence: therapeutic

PMID:21749277 PMID:22580338

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

CTD Direct Evidence: marker/mechanism

PMID:25199511 PMID:32512068

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

CTD Direct Evidence: marker/mechanism

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 5

CTD Direct Evidence: marker/mechanism

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

Cd82 molecule

CTD Direct Evidence: therapeutic

NCBI chr 3:79,387,361...79,431,847
Ensembl chr 3:79,385,887...79,431,809

G

cadherin 1

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:19839049 PMID:22580338

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 2

CTD Direct Evidence: marker/mechanism

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

G

cyclin-dependent kinase inhibitor 2A

CTD Direct Evidence: marker/mechanism

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

cofilin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587

G

chitinase 3 like 1

CTD Direct Evidence: marker/mechanism

NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787

G

cholinergic receptor nicotinic alpha 7 subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240

G

chromosome segregation 1 like

CTD Direct Evidence: marker/mechanism

NCBI chr 3:155,641,104...155,678,866
Ensembl chr 3:155,641,166...155,678,865

G

cystatin B

CTD Direct Evidence: marker/mechanism

PMID:19747051 PMID:22287159

NCBI chr20:10,245,462...10,247,505
Ensembl chr20:10,245,462...10,247,526

G

C-terminal binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:187,782,064...187,918,115
Ensembl chr 1:187,782,682...187,920,222

G

catenin beta 1

CTD Direct Evidence: marker/mechanism

PMID:23707762 PMID:26990689

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cathepsin B

CTD Direct Evidence: marker/mechanism

PMID:19700239 PMID:19747051

NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500

G

cathepsin D

CTD Direct Evidence: marker/mechanism

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cathepsin S

CTD Direct Evidence: marker/mechanism

NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483

G

cytosolic thiouridylase subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:94,115,431...94,121,224
Ensembl chr 1:94,115,420...94,121,221

G

cytosolic thiouridylase subunit 2

CTD Direct Evidence: marker/mechanism

NCBI chr19:50,539,184...50,544,629
Ensembl chr19:50,539,352...50,544,623

G

C-X-C motif chemokine ligand 12

CTD Direct Evidence: marker/mechanism

PMID:19700239 PMID:25231984 PMID:25753200

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine receptor 4

CTD Direct Evidence: marker/mechanism

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

cytochrome P450, family 2, subfamily e, polypeptide 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

DEK proto-oncogene

CTD Direct Evidence: marker/mechanism

PMID:21291860 PMID:27811057

NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808

G

distal-less homeobox 4

CTD Direct Evidence: marker/mechanism

NCBI chr10:80,085,037...80,090,434
Ensembl chr10:80,085,465...80,090,456

G

dystrophin

CTD Direct Evidence: marker/mechanism

NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207

G

DNA methyltransferase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

endothelin receptor type B

CTD Direct Evidence: marker/mechanism

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

eukaryotic translation elongation factor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183

G

epidermal growth factor

CTD Direct Evidence: marker/mechanism

PMID:15802018 PMID:22869556 PMID:23064031 PMID:24587105 PMID:27634460

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

CTD Direct Evidence: marker/mechanism

PMID:18844224 PMID:23867902

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

eukaryotic translation initiation factor 4E

CTD Direct Evidence: marker/mechanism

NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683

G

elongator acetyltransferase complex subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:71,453,338...71,505,833
Ensembl chr 5:71,456,310...71,505,762

G

elongator acetyltransferase complex subunit 3

CTD Direct Evidence: marker/mechanism

NCBI chr15:39,754,635...39,816,482
Ensembl chr15:39,754,632...39,816,445

G

engrailed homeobox 1

CTD Direct Evidence: marker/mechanism

NCBI chr13:31,750,892...31,756,477
Ensembl chr13:31,751,545...31,755,943

G

enolase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336

G

endothelial PAS domain protein 1

CTD Direct Evidence: marker/mechanism

PMID:26735578 PMID:30090327

NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228

G

erythropoietin

CTD Direct Evidence: marker/mechanism

NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946

G

erythropoietin receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257

G

EGFR pathway substrate 8, signaling adaptor

CTD Direct Evidence: marker/mechanism

NCBI chr 4:170,388,378...170,486,873
Ensembl chr 4:170,388,378...170,486,873

G

estrogen receptor 1

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:26990689 PMID:27366082 PMID:35044086

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

family with sequence similarity 83, member A

CTD Direct Evidence: marker/mechanism

NCBI chr 7:89,522,826...89,547,284
Ensembl chr 7:89,522,826...89,547,388

G

fibroblast growth factor receptor 4

ClinVar Annotator: match by term: Cancer progression and tumor cell motility

PMID:11830541 PMID:25741868 PMID:26675719 PMID:33116287

NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242

G

fibronectin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

forkhead box P1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:131,559,599...132,155,092
Ensembl chr 4:131,564,756...132,112,258

G

ferritin heavy chain 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

ferritin light chain 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725

G

GRB2-associated binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:151,429,844...151,625,708
Ensembl chr 1:151,429,695...151,625,031

G

glycine rich extracellular protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:12,727,164...12,748,629
Ensembl chr10:12,727,166...12,741,819

G

H19 imprinted maternally expressed transcript

CTD Direct Evidence: marker/mechanism

NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134

G

histone deacetylase 3

CTD Direct Evidence: marker/mechanism

NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856

G

hepatocyte growth factor

CTD Direct Evidence: marker/mechanism

PMID:9932610 PMID:15654357

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

hypoxia inducible factor 1 subunit alpha

CTD Direct Evidence: marker/mechanism

PMID:12811834 PMID:29501572

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

high mobility group AT-hook 2

CTD Direct Evidence: marker/mechanism

NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130

G

heme oxygenase 1

CTD Direct Evidence: therapeutic

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

homeo box B13

CTD Direct Evidence: marker/mechanism

NCBI chr10:81,160,498...81,162,777
Ensembl chr10:81,160,498...81,162,777

G

homeo box B3

CTD Direct Evidence: marker/mechanism

NCBI chr10:81,258,739...81,314,134
Ensembl chr10:81,299,357...81,313,107

G

heparanase

CTD Direct Evidence: marker/mechanism

NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010

G

HRas proto-oncogene, GTPase

CTD Direct Evidence: marker/mechanism

NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615

G

inhibitor of DNA binding 4

CTD Direct Evidence: marker/mechanism

NCBI chr17:16,389,387...16,391,956
Ensembl chr17:16,389,387...16,392,470

G

insulin-like growth factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 1 beta

CTD Direct Evidence: marker/mechanism

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor antagonist

CTD Direct Evidence: therapeutic

NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445

G

interleukin 6

CTD Direct Evidence: marker/mechanism

PMID:26101800 PMID:26284488

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

iron responsive element binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:55,228,080...55,311,613
Ensembl chr 8:55,228,085...55,311,611

G

integrin subunit alpha 5

CTD Direct Evidence: marker/mechanism

NCBI chr 7:134,478,963...134,502,837
Ensembl chr 7:134,478,968...134,502,837

G

integrin subunit beta 1

CTD Direct Evidence: marker/mechanism

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

inositol-tetrakisphosphate 1-kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 6:121,710,750...121,844,501
Ensembl chr 6:121,710,755...121,844,107

G

potassium voltage-gated channel subfamily D member 2

CTD Direct Evidence: marker/mechanism

NCBI chr 4:49,775,812...50,277,746
Ensembl chr 4:49,776,246...50,277,728

G

lysine demethylase 1A

CTD Direct Evidence: marker/mechanism

NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319

G

keratin 19

CTD Direct Evidence: marker/mechanism

NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799

G

keratin 7

CTD Direct Evidence: marker/mechanism

NCBI chr 7:132,528,881...132,545,052
Ensembl chr 7:132,528,895...132,545,052

G

lactate dehydrogenase B

CTD Direct Evidence: marker/mechanism

NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403

G

lymphoid enhancer binding factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794

G

lin-28 homolog A

CTD Direct Evidence: marker/mechanism

NCBI chr 5:146,227,119...146,244,122
Ensembl chr 5:146,227,119...146,244,122

G

lysyl oxidase-like 2

CTD Direct Evidence: marker/mechanism

NCBI chr15:44,683,449...44,773,067
Ensembl chr15:44,683,880...44,773,067

G

mitogen activated protein kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

CTD Direct Evidence: marker/mechanism

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MET proto-oncogene, receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

microRNA 141

CTD Direct Evidence: therapeutic

NCBI chr 4:157,523,239...157,523,332
Ensembl chr 4:157,523,239...157,523,332

G

microRNA 155

CTD Direct Evidence: marker/mechanism

NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718

G

microRNA 186

CTD Direct Evidence: marker/mechanism

NCBI chr 2:246,582,806...246,582,891
Ensembl chr 2:246,582,806...246,582,891

G

microRNA 191

CTD Direct Evidence: marker/mechanism

NCBI chr 8:109,264,098...109,264,188

G

microRNA 200b

CTD Direct Evidence: therapeutic

NCBI chr 5:166,649,272...166,649,366
Ensembl chr 5:166,649,272...166,649,366

G

microRNA 200c

CTD Direct Evidence: therapeutic

NCBI chr 4:157,523,679...157,523,747

G

microRNA 21

CTD Direct Evidence: marker/mechanism

PMID:26101800 PMID:29501572

NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348

G

microRNA 217

CTD Direct Evidence: marker/mechanism

NCBI chr14:102,531,505...102,531,609
Ensembl chr14:102,531,505...102,531,609

G

microRNA 346

CTD Direct Evidence: marker/mechanism

PMID:27501413 PMID:27777383

NCBI chr16:10,218,118...10,218,215
Ensembl chr16:10,218,118...10,218,215

G

microRNA 497

CTD Direct Evidence: marker/mechanism

NCBI chr10:54,951,514...54,951,582
Ensembl chr10:54,951,505...54,951,584

G

microRNA 532

CTD Direct Evidence: marker/mechanism

NCBI chr X:15,247,315...15,247,393
Ensembl chr X:15,247,315...15,247,393

G

microRNA 708

CTD Direct Evidence: therapeutic

NCBI chr 1:150,599,876...150,599,963
Ensembl chr 1:150,599,876...150,599,963

G

microRNA 874

CTD Direct Evidence: therapeutic

NCBI chr17:6,620,649...6,620,724
Ensembl chr17:6,620,649...6,620,724

G

matrix metallopeptidase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 14

CTD Direct Evidence: marker/mechanism

NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864

G

matrix metallopeptidase 2

CTD Direct Evidence: marker/mechanism

PMID:18398872 PMID:19770485 PMID:22321834 PMID:23707804 PMID:34278709

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 3

CTD Direct Evidence: marker/mechanism

PMID:20188714 PMID:26284488

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 9

CTD Direct Evidence: marker/mechanism

PMID:19617202 PMID:19700239 PMID:20188714 PMID:21187089 PMID:22503731 More...

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

metallothionein 2A

CTD Direct Evidence: marker/mechanism

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

metallothionein 3

CTD Direct Evidence: marker/mechanism

NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158

G

metadherin

CTD Direct Evidence: marker/mechanism

NCBI chr 7:65,306,464...65,365,647
Ensembl chr 7:65,306,400...65,364,413

G

MYD88, innate immune signal transduction adaptor

CTD Direct Evidence: marker/mechanism

NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415

G

myosin, heavy chain 9

CTD Direct Evidence: marker/mechanism

NCBI chr 7:109,343,718...109,424,457
Ensembl chr 7:109,343,706...109,424,457

G

myosin light chain kinase

CTD Direct Evidence: marker/mechanism

PMID:10232591 PMID:12970723

NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261

G

neural cell adhesion molecule 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014

G

NIMA-related kinase 2

CTD Direct Evidence: marker/mechanism

NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051

G

NFE2 like bZIP transcription factor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NME/NM23 nucleoside diphosphate kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:78,907,036...78,929,659
Ensembl chr10:78,906,083...78,916,408

G

notch receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088

G

neuregulin 1

CTD Direct Evidence: marker/mechanism

NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884

G

NUAK family kinase 1

CTD Direct Evidence: marker/mechanism

PMID:26213588 PMID:26873845

NCBI chr 7:19,330,034...19,401,918
Ensembl chr 7:19,329,933...19,401,913

G

p21 (RAC1) activated kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:152,111,172...152,226,390
Ensembl chr 1:152,111,188...152,226,383

G

paired box 6

CTD Direct Evidence: marker/mechanism

NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014

G

programmed cell death 4

CTD Direct Evidence: marker/mechanism

NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275

G

phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 2:182,628,299...182,671,584
Ensembl chr 2:182,628,300...182,671,598

G

pyruvate kinase M1/2

CTD Direct Evidence: marker/mechanism

PMID:15048980 PMID:15654357

NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599

G

plasminogen activator, urokinase

CTD Direct Evidence: marker/mechanism

PMID:14644129 PMID:26284488

NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775

G

plasminogen activator, urokinase receptor

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:22261521 PMID:12198772

NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595

G

protein phosphatase 1, regulatory subunit 12B

CTD Direct Evidence: marker/mechanism

NCBI chr13:46,199,418...46,397,108
Ensembl chr13:46,201,251...46,397,108

G

peroxiredoxin 2

CTD Direct Evidence: marker/mechanism

NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194

G

phosphatase and tensin homolog

CTD Direct Evidence: therapeutic

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

protein tyrosine kinase 2

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:12811834 PMID:25199511

NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783

G

Pvt1 oncogene

CTD Direct Evidence: marker/mechanism

NCBI chr 7:93,656,528...93,879,938

G

RAB27A, member RAS oncogene family

CTD Direct Evidence: marker/mechanism

NCBI chr 8:73,782,730...73,836,630
Ensembl chr 8:73,782,694...73,847,829

G

RAB27B, member RAS oncogene family

CTD Direct Evidence: marker/mechanism

NCBI chr18:63,597,554...63,794,124
Ensembl chr18:63,600,937...63,757,180

G

RAS protein activator like 2

CTD Direct Evidence: marker/mechanism

NCBI chr13:69,279,882...69,569,161
Ensembl chr13:69,258,622...69,569,940

G

RNA binding motif protein 38

CTD Direct Evidence: therapeutic

NCBI chr 3:161,801,577...161,814,381
Ensembl chr 3:161,801,577...161,814,381

G

reversion-inducing-cysteine-rich protein with kazal motifs

CTD Direct Evidence: therapeutic

NCBI chr 5:58,102,961...58,169,516
Ensembl chr 5:58,102,981...58,169,502

G

RELA proto-oncogene, NF-kB subunit

CTD Direct Evidence: marker/mechanism

PMID:19896475 PMID:29501572

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ras homolog family member A

CTD Direct Evidence: marker/mechanism

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

ring finger protein 207

CTD Direct Evidence: marker/mechanism

NCBI chr 5:162,815,351...162,828,325
Ensembl chr 5:162,815,357...162,828,375

G

ribosomal protein L3-like

CTD Direct Evidence: marker/mechanism

NCBI chr10:13,753,914...13,764,458
Ensembl chr10:13,753,886...13,764,457

G

ribosomal protein S6 kinase A3

CTD Direct Evidence: marker/mechanism

NCBI chr X:35,517,306...35,623,296
Ensembl chr X:35,517,306...35,623,207

G

ribosomal protein SA

CTD Direct Evidence: marker/mechanism

NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247

G

S100 calcium binding protein A11

CTD Direct Evidence: marker/mechanism

NCBI chr 2:179,191,688...179,197,098
Ensembl chr 2:179,191,715...179,197,044

G

S100 calcium-binding protein A4

CTD Direct Evidence: marker/mechanism

NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254

G

sphingosine-1-phosphate receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:19,503,276...19,514,169
Ensembl chr 8:19,502,627...19,523,574

G

septin 9

CTD Direct Evidence: marker/mechanism

NCBI chr10:102,409,798...102,579,056
Ensembl chr10:102,409,711...102,579,055

G

Set nuclear proto-oncogene

CTD Direct Evidence: marker/mechanism

NCBI chr 3:13,334,564...13,345,598
Ensembl chr 3:13,335,041...13,363,567

G

solute carrier family 39 member 10

CTD Direct Evidence: marker/mechanism

NCBI chr 9:54,836,841...54,960,325
Ensembl chr 9:54,876,141...54,960,325

G

solute carrier family 6 member 12

CTD Direct Evidence: marker/mechanism

NCBI chr 4:154,585,386...154,603,750
Ensembl chr 4:154,585,500...154,603,750

G

sphingomyelin phosphodiesterase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:159,892,946...159,896,789
Ensembl chr 1:159,892,859...159,896,794

G

snail family transcriptional repressor 1

CTD Direct Evidence: marker/mechanism

PMID:22580338 PMID:24014025

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

G

snail family transcriptional repressor 2

CTD Direct Evidence: marker/mechanism

NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200

G

superoxide dismutase 2

CTD Direct Evidence: marker/mechanism

PMID:10853026 PMID:11053990 PMID:15048980 PMID:15654357 PMID:21749277 More...

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

sortilin related receptor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513

G

SRY-box transcription factor 11

CTD Direct Evidence: marker/mechanism

NCBI chr 6:44,008,333...44,010,354
Ensembl chr 6:44,008,340...44,010,354

G

SRY-box transcription factor 9

CTD Direct Evidence: marker/mechanism

NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994

G

Sp1 transcription factor

CTD Direct Evidence: marker/mechanism

PMID:26317792 PMID:35072892

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

SRC proto-oncogene, non-receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

PMID:18844224 PMID:21291860

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

signal transducer and activator of transcription 3

CTD Direct Evidence: marker/mechanism

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

small ubiquitin-like modifier 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:61,078,790...61,108,697
Ensembl chr 9:61,077,435...61,108,761

G

T-box transcription factor 15

CTD Direct Evidence: marker/mechanism

NCBI chr 2:186,576,650...186,687,748
Ensembl chr 2:186,576,676...186,687,663

G

transferrin

CTD Direct Evidence: marker/mechanism

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511

G

tissue factor pathway inhibitor 2

RGD

NCBI chr 4:31,981,786...31,986,707
Ensembl chr 4:31,982,178...31,986,600

G

transforming growth factor, beta 1

CTD Direct Evidence: marker/mechanism

PMID:23992306 PMID:24727557 PMID:24793912 PMID:25884904 PMID:26896736 More...

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

TGFB-induced factor homeobox 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:110,748,094...110,757,714
Ensembl chr 9:110,720,921...110,757,802

G

TIMP metallopeptidase inhibitor 1

CTD Direct Evidence: therapeutic

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

TIMP metallopeptidase inhibitor 3

CTD Direct Evidence: therapeutic

NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839

G

transketolase

CTD Direct Evidence: marker/mechanism

NCBI chr16:5,723,764...5,748,702
Ensembl chr16:5,723,762...5,748,698

G

talin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:57,787,670...57,817,900
Ensembl chr 5:57,787,943...57,817,900

G

toll-like receptor 4

CTD Direct Evidence: marker/mechanism

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

transmembrane protein 139

CTD Direct Evidence: marker/mechanism

NCBI chr 4:71,147,072...71,149,151
Ensembl chr 4:71,146,724...71,167,399

G

tumor necrosis factor

CTD Direct Evidence: marker/mechanism

PMID:22199285 PMID:23431386 PMID:23899529 PMID:24613819

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53 binding protein, 2

CTD Direct Evidence: marker/mechanism

NCBI chr13:94,088,769...94,145,436
Ensembl chr13:94,088,709...94,145,432

G

tripartite motif-containing 47

CTD Direct Evidence: marker/mechanism

NCBI chr10:101,337,573...101,342,044
Ensembl chr10:101,337,573...101,342,044

G

transient receptor potential cation channel, subfamily M, member 7

CTD Direct Evidence: marker/mechanism

NCBI chr 3:114,046,258...114,134,799
Ensembl chr 3:114,046,258...114,135,190

G

twist family bHLH transcription factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653

G

thioredoxin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

G

ubiquilin 1

CTD Direct Evidence: marker/mechanism

NCBI chr17:6,439,002...6,477,096
Ensembl chr17:6,439,002...6,477,090

G

vimentin

CTD Direct Evidence: marker/mechanism

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

XPC complex subunit, DNA damage recognition and repair factor

CTD Direct Evidence: marker/mechanism

NCBI chr 4:123,993,670...124,020,922
Ensembl chr 4:123,993,666...124,021,010

G

X-ray repair cross complementing 3

CTD Direct Evidence: marker/mechanism

NCBI chr 6:130,863,405...130,873,765
Ensembl chr 6:130,863,959...130,872,444

G

Yes1 associated transcriptional regulator

CTD Direct Evidence: marker/mechanism

NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010

G

zinc finger and BTB domain containing 16

CTD Direct Evidence: marker/mechanism

NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011

G

zinc finger E-box binding homeobox 1

CTD Direct Evidence: marker/mechanism

NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214

G

zinc finger E-box binding homeobox 2

CTD Direct Evidence: marker/mechanism

NCBI chr 3:29,214,581...29,344,890
Ensembl chr 3:29,218,301...29,345,157

G

zinc finger protein 36

CTD Direct Evidence: therapeutic

NCBI chr 1:83,669,084...83,671,564
Ensembl chr 1:83,669,084...83,671,564

G

zinc finger protein 367

CTD Direct Evidence: marker/mechanism

NCBI chr17:965,161...984,290
Ensembl chr17:965,161...984,287

G

zinc finger RNA binding protein

CTD Direct Evidence: marker/mechanism

NCBI chr 2:61,137,611...61,200,322
Ensembl chr 2:61,137,611...61,200,322

Neoplasm Metastasis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

CTD Direct Evidence: marker/mechanism

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 4

CTD Direct Evidence: marker/mechanism

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

angiotensin I converting enzyme

CTD Direct Evidence: marker/mechanism

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

atypical chemokine receptor 3

CTD Direct Evidence: marker/mechanism

NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237

G

acyl-CoA synthetase bubblegum family member 1

associated with pheochromocytoma

RGD

NCBI chr 8:54,991,294...55,047,276
Ensembl chr 8:54,991,296...55,047,391

G

activin A receptor type 2A

exacerbates

associated with colon cancer;mRNA,protein:decreased expression:colon (human)

RGD

NCBI chr 3:33,204,961...33,292,673
Ensembl chr 3:33,205,523...33,289,968

G

adhesion G protein-coupled receptor B1

associated with colorectal cancer

RGD

NCBI chr 7:106,404,827...106,476,902
Ensembl chr 7:106,404,958...106,476,902

G

adenosine A2B receptor

CTD Direct Evidence: marker/mechanism

NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772

G

angiotensin II receptor, type 1a

CTD Direct Evidence: marker/mechanism

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

angiotensin II receptor, type 2

CTD Direct Evidence: marker/mechanism

NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057

G

aryl hydrocarbon receptor

CTD Direct Evidence: therapeutic

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

akirin 2

RGD

NCBI chr 5:49,108,231...49,122,566
Ensembl chr 5:49,108,220...49,122,568

G

AKT serine/threonine kinase 2

associated with Mammary Neoplasms, Experimental

RGD

NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817

G

aldolase, fructose-bisphosphate A

CTD Direct Evidence: marker/mechanism

NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182

G

ALK receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

PMID:22986231 PMID:22999080

NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034

G

arachidonate 5-lipoxygenase

CTD Direct Evidence: marker/mechanism

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

adhesion molecule with Ig like domain 2

Liver Metastasis

RGD

NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695

G

angiopoietin-like 4

CTD Direct Evidence: therapeutic

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

ANTXR cell adhesion molecule 1

associated with Mammary Neoplasms, Experimental;

RGD

NCBI chr 4:119,590,770...119,778,232
Ensembl chr 4:119,590,771...119,778,232

G

annexin A1

treatment

associated with Mammary Neoplasms, Experimental;protein:increased expression:lung
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20308542 PMID:9514092 PMID:20308542 PMID:20821804 PMID:20821804

RGD:2306939, RGD:7421563, RGD:7421541, RGD:7421541

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

annexin A4

CTD Direct Evidence: marker/mechanism

NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161

G

annexin A7

associated with Breast Neoplasms;protein:increased expression:breast
associated with Prostatic Neoplasms;protein:decreased expression:prostate gland

RGD

PMID:15073110 PMID:11287641

RGD:2292655, RGD:2292656

NCBI chr15:3,821,798...3,849,659
Ensembl chr15:3,821,845...3,849,385

G

apolipoprotein E

RGD

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

Rho GDP dissociation inhibitor alpha

CTD Direct Evidence: marker/mechanism

NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023

G

AT-rich interaction domain 1A

disease_progression

in lung; associated with hepatocellular carcinoma

RGD

NCBI chr 5:145,908,173...145,981,552
Ensembl chr 5:145,908,181...145,985,564

G

ATPase H+ transporting V1 subunit C1

associated with Mammary Neoplasms, Experimental

RGD

NCBI chr 7:69,834,464...69,872,278
Ensembl chr 7:69,834,463...69,872,278

G

Axl receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265

G

antizyme inhibitor 1

associated with stomach cancer;RNA:increased editing:stomach
associated with colorectal cancer;RNA:increased editing:colorectum

RGD

PMID:30563560 PMID:29925690

RGD:14700703, RGD:14700704

NCBI chr 7:69,654,773...69,681,578
Ensembl chr 7:69,654,663...69,681,578

G

BCL2 associated X, apoptosis regulator

associated with Carcinoma, Infiltrating Duct

RGD

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

associated with Breast Neoplasms
associated with Carcinoma, Renal Cell

RGD

PMID:16826579 PMID:12810203

RGD:2293020, RGD:2293021

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bone morphogenetic protein 6

severity

associated with Prostatic Neoplasms;protein:increased expression:bone

RGD

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

bone morphogenetic protein 7

disease_progression

associated with Breast Neoplasms;protein:increased expression:breast
associated with Prostatic Neoplasms;mRNA:increased expression:bone

RGD

PMID:17895257 PMID:12539225

RGD:2289029, RGD:2289033

NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788

G

B-Raf proto-oncogene, serine/threonine kinase

onset

associated with Melanoma; DNA:mutations: :

RGD

NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463

G

bromodomain containing 4

RGD

NCBI chr 7:11,216,446...11,296,029
Ensembl chr 7:11,216,446...11,295,539

G

BRMS1, transcriptional repressor and anoikis regulator

CTD Direct Evidence: therapeutic

NCBI chr 1:202,345,766...202,355,028
Ensembl chr 1:202,345,704...202,355,028

G

basigin

CTD Direct Evidence: marker/mechanism

NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387

G

calcium binding protein 39

associated with hepatocellular carcinoma;

RGD

NCBI chr 9:86,463,095...86,524,545
Ensembl chr 9:86,463,095...86,524,544

G

calcyclin binding protein

associated with pancreatic neoplasms

RGD

NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177

G

calmodulin-like 3

ameliorates

associated with hepatocellular carcinoma; human cells in mouse model
associated with hepatocellular carcinoma; protein:decreased expression:liver (human)

PMID:29445139 PMID:29445139

RGD:151665319, RGD:151665319

NCBI chr17:66,419,844...66,423,083
Ensembl chr17:66,419,882...66,423,175

G

cyclase associated actin cytoskeleton regulatory protein 1

associated with Pancreatic Neoplasms; mRNA, protein:increased expression:pancreas

RGD

NCBI chr 5:135,142,108...135,168,885
Ensembl chr 5:135,142,112...135,168,769

G

caspase 3

associated with Breast Neoplasms

RGD

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

CTD Direct Evidence: therapeutic

PMID:12538496 PMID:22580338 PMID:23518002

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

caveolin 1

treatment

associated with Mammary Neoplasms, Experimental
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20562527 PMID:15355971 PMID:15334058

RGD:2289106, RGD:8661780

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

chromobox 4

associated with Carcinoma, Hepatocellular;

RGD

NCBI chr10:104,337,140...104,343,210
Ensembl chr10:104,336,876...104,356,706

G

chromobox 5

associated with Lung Neoplasms;

RGD

NCBI chr 7:134,333,165...134,376,102
Ensembl chr 7:134,331,335...134,375,022

G

C-C motif chemokine ligand 2

associated with Mammary Neoplasms, Experimental

RGD

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

CTD Direct Evidence: marker/mechanism

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 3

RGD

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 5

treatment

associated with Animal Mammary Neoplasms;

RGD

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cellular communication network factor 4

CTD Direct Evidence: marker/mechanism

NCBI chr 7:98,645,238...98,677,253
Ensembl chr 7:98,645,182...98,677,248

G

cyclin A2

associated with Seminoma;protein:increased expression:testis

RGD

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin D1

treatment

associated with Carcinoma, Non-Small-Cell Lung;mRNA:splice variant
associated with stomach cancer; human cells in mouse model

RGD

PMID:18715616 PMID:27431311

RGD:13434926, RGD:152995400

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D2

associated with Breast Neoplasms;DNA:hypermethylated:brain

RGD

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin E1

disease_progression

protein:altered processing
associated with non-small cell lung carcinoma

RGD

PMID:17671189 PMID:11212263

RGD:2289229, RGD:13673913

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

C-C motif chemokine receptor 5

CTD Direct Evidence: marker/mechanism

NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260

G

CD274 molecule

disease_progression

associated with ovarian cancer

RGD

NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450

G

CD44 molecule

associated with Carcinoma, Renal Cell;protein:increased expression:kidney
CTD Direct Evidence: marker/mechanism
associated with Breast Neoplasm;protein:increased expression:liver

CTD
RGD

PMID:23098472 PMID:18026989 PMID:17991717

RGD:2289347, RGD:2289349

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

Cd82 molecule

associated with Carcinoma, Hepatocellular;mRNA:decreased expression
CTD Direct Evidence: therapeutic
associated with Prostatic Neoplasms;mRNA:decreased expression:bone
associated with Carcinoma, Infiltrating Duct;mRNA:decreased expression:brain
associated with Prostatic Neoplasms;DNA:loss of heterozygosity

CTD
RGD

PMID:20075392 PMID:11275982 PMID:12806379 PMID:15592684 PMID:9831222 More...

RGD:2289407, RGD:2289402, RGD:2289400, RGD:68869, RGD:2289425

NCBI chr 3:79,387,361...79,431,847
Ensembl chr 3:79,385,887...79,431,809

G

CD86 molecule

mRNA:decreased expression:mediastinal lymph node (rat)

RGD

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

cadherin 1

treatment

associated with Prostatic Neoplasms
associated with stomach cancer; human cells in mouse model
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:17520682 PMID:22580338 PMID:18008331 PMID:27431311

RGD:2289488, RGD:152995400

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 2

CTD Direct Evidence: marker/mechanism

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

G

cyclin dependent kinase like 2

CTD Direct Evidence: marker/mechanism

NCBI chr14:16,027,381...16,063,257
Ensembl chr14:16,028,363...16,063,252

G

cyclin-dependent kinase inhibitor 1A

associated with Melanoma;

RGD

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2A

associated with Paraganglioma, Extra-Adrenal;DNA:hypermethylation

RGD

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

cofilin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587

G

glycoprotein hormones, alpha polypeptide

associated with Breast Neoplasms;protein:increased expression:serum

RGD

NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191

G

checkpoint kinase 1

associated with Pancreatic Neoplasms

RGD

NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009

G

component of inhibitor of nuclear factor kappa B kinase complex

associated with prostate adenocarcinoma

RGD

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

capicua transcriptional repressor

CTD Direct Evidence: marker/mechanism

NCBI chr 1:80,853,920...80,880,537
Ensembl chr 1:80,853,920...80,880,532

G

claudin 7

RGD

NCBI chr10:54,689,684...54,692,177
Ensembl chr10:54,689,987...54,692,171

G

chloride intracellular channel 1

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712

G

clusterin

associated with Breast Neoplasms

RGD

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

cAMP responsive element binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

colony stimulating factor 1

associated with Prostatic Neoplasms

RGD

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

colony stimulating factor 1 receptor

exacerbates

associated with Prostatic Neoplasms
associated with breast cancer
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:1390197 PMID:18510570 PMID:25005824

RGD:2293638, RGD:150524287

NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415

G

colony stimulating factor 3

CTD Direct Evidence: therapeutic

PMID:7543699 PMID:9018096

NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603

G

cystatin C

protein:decreased expression:cerebrospinal fluid

RGD

NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822

G

cystatin A

CTD Direct Evidence: marker/mechanism

NCBI chr11:64,620,483...64,631,488
Ensembl chr11:64,620,483...64,631,488

G

cytotoxic T-lymphocyte-associated protein 4

disease_progression

associated with Mammary Neoplasms, Experimental

RGD

PMID:15701862 PMID:18049334

RGD:4891518, RGD:7204722

NCBI chr 9:62,318,874...62,325,978
Ensembl chr 9:62,319,312...62,324,963

G

catenin beta 1

associated with Prostatic Neoplasms
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:29106415 PMID:18008331

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cathepsin B

protein:increased expression:cerebrospinal fluid

RGD

NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500

G

cathepsin D

protein:increased expression:oral cavity, oropharynx, hypopharynx (human)

RGD

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cathepsin H

protein:increased expression:cerebrospinal fluid

RGD

NCBI chr 8:90,608,941...90,627,824
Ensembl chr 8:90,608,941...90,627,824

G

cytosolic thiouridylase subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:94,115,431...94,121,224
Ensembl chr 1:94,115,420...94,121,221

G

cytosolic thiouridylase subunit 2

CTD Direct Evidence: marker/mechanism

NCBI chr19:50,539,184...50,544,629
Ensembl chr19:50,539,352...50,544,623

G

C-X3-C motif chemokine receptor 1

susceptibility

associated with Breast Neoplasms

RGD

NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014

G

C-X-C motif chemokine ligand 12

treatment

associated with Pancreatic Neoplasms
CTD Direct Evidence: marker/mechanism
associated with Pancreatic Carcinoma

CTD
RGD

PMID:21312072 PMID:23743303 PMID:12761880 PMID:26330165

RGD:2317610, RGD:10398726

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine receptor 3

associated with Mammary Neoplasms, Experimental

RGD

NCBI chr X:66,844,318...66,846,969
Ensembl chr X:66,844,318...66,846,969

G

C-X-C motif chemokine receptor 4

ameliorates
severity
disease_progression

CTD Direct Evidence: marker/mechanism
associated with lung non-small cell carcinoma;mRNA,protein:increased expression:lung (human)
associated with Otorhinolaryngologic Neoplasms;mRNA,protein:increased expression:Laryngeal and hypopharyngeal tissue (human)
associated with lung non-small cell carcinoma; protein:increased expression:lung (human)
associated with oral squamous cell carcinoma
associated with pancreatic cancer
associated with osteosarcoma;protein:increased expression:bone (human)
human cells in mouse model;associated with lung cancer
associated with lung cancer; human cells in mouse model

PMID:21312072 PMID:23743303 PMID:26546437 PMID:16322285 PMID:18487224 More...

RGD:152023746, RGD:152177479, RGD:152177478, RGD:152177476, RGD:152177475, RGD:152025556, RGD:152023745, RGD:152023741, RGD:151708730

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

cytochrome P450, family 19, subfamily a, polypeptide 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

DAB2 interacting protein

severity

associated with colorectal cancer;protein:decreased expression:colorectum (human)

RGD

NCBI chr 3:18,915,290...19,086,282
Ensembl chr 3:18,915,290...19,086,280

G

death associated protein kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991

G

death-domain associated protein

RGD

NCBI chr20:4,970,090...4,976,145
Ensembl chr20:4,970,092...4,975,843

G

decorin

associated with Breast Neoplasms

RGD

NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270

G

discoidin domain receptor tyrosine kinase 1

severity

mRNA:increased expression:ovary (human)
protein:increased expression:bone (human)

RGD

PMID:28743276 PMID:29039472

RGD:151347541, RGD:151347601

NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468

G

discoidin domain receptor tyrosine kinase 2

ameliorates

associated with melanoma;

RGD

NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363

G

DEAD-box helicase 3, X-linked

human cells in mouse model

RGD

NCBI chr X:9,479,532...9,493,169
Ensembl chr X:9,479,532...9,493,168

G

DEK proto-oncogene

CTD Direct Evidence: marker/mechanism

NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808

G

dihydrofolate reductase

disease_progression

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:19159907 PMID:8149482

NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713

G

iodothyronine deiodinase 3

CTD Direct Evidence: marker/mechanism

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

G

dystrophin

CTD Direct Evidence: marker/mechanism

NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207

G

DNA methyltransferase 3 beta

associated with Uterine Cervical Neoplasms;

RGD

NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124

G

dihydropyrimidine dehydrogenase

treatment

associated with Colonic Neoplasms
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:17611699 PMID:11383214

NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982

G

E2F transcription factor 1

severity

protein:increased expression:bone (human)

RGD

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

E2F transcription factor 8

CTD Direct Evidence: marker/mechanism

NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098

G

endothelin 1

RGD

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin receptor type A

associated with Bladder Neoplasms

RGD

NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049

G

eukaryotic translation elongation factor 1 beta 2

CTD Direct Evidence: marker/mechanism

PMID:17085005 PMID:20562527

NCBI chr 9:64,580,163...64,582,737
Ensembl chr 9:64,579,893...64,582,737

G

eukaryotic translation elongation factor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183

G

ephrin B2

associated with cholangiocarcinoma;protein:increased expression:biliary ductule (human)

RGD

NCBI chr16:80,783,389...80,827,420
Ensembl chr16:80,783,417...80,824,391

G

epidermal growth factor

CTD Direct Evidence: marker/mechanism

PMID:21942447 PMID:23064031

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

CTD Direct Evidence: marker/mechanism

PMID:17369752 PMID:17575224 PMID:23867902

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

euchromatic histone lysine methyltransferase 2

associated with lung neoplasms;
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20940408 PMID:25115793 PMID:20940408

NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547

G

eukaryotic translation initiation factor 1A, X-linked

CTD Direct Evidence: marker/mechanism

NCBI chr X:35,498,698...35,513,402
Ensembl chr X:35,498,517...35,513,335

G

eukaryotic translation initiation factor 4A2

CTD Direct Evidence: marker/mechanism

NCBI chr11:77,764,126...77,770,810
Ensembl chr11:77,764,124...77,770,781

G

elongator acetyltransferase complex subunit 3

CTD Direct Evidence: marker/mechanism

NCBI chr15:39,754,635...39,816,482
Ensembl chr15:39,754,632...39,816,445

G

EMAP like 4

CTD Direct Evidence: marker/mechanism

PMID:22986231 PMID:22999080

NCBI chr 6:11,219,545...11,334,824
Ensembl chr 6:11,219,566...11,334,879

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827

G

epithelial cell adhesion molecule

RGD

NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127

G

erythropoietin

CTD Direct Evidence: marker/mechanism

NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946

G

erythropoietin receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257

G

erb-b2 receptor tyrosine kinase 2

rat gene in a mouse model
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16984552 PMID:11238891

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

erb-b2 receptor tyrosine kinase 3

disease_progression

associated with Prostatic Neoplasms;protein:alternative form
associated with lung adenocarcinoma
CTD Direct Evidence: marker/mechanism
associated with Prostatic Neoplasms;protein:increased expression, altered localization:bone, nucleus

CTD
RGD

PMID:28114269 PMID:18559590 PMID:26254096 PMID:17634423

RGD:2298500, RGD:126790470, RGD:2289944

NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525

G

erb-b2 receptor tyrosine kinase 4

disease_progression

associated with lung adenocarcinoma

RGD

NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595

G

ERCC excision repair 1, endonuclease non-catalytic subunit

disease_progression

associated with Melanoma
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20801905 PMID:26202595

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

ERCC excision repair 4, endonuclease catalytic subunit

CTD Direct Evidence: marker/mechanism

NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369

G

endoplasmic reticulum protein 29

CTD Direct Evidence: marker/mechanism

NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376

G

estrogen receptor 1

CTD Direct Evidence: marker/mechanism

PMID:20104649 PMID:35044086

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

ETS variant transcription factor 4

CTD Direct Evidence: marker/mechanism

NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974

G

enhancer of zeste 2 polycomb repressive complex 2 subunit

associated with stomach cancer;protein:increased expression:stomach
associated with osteosarcoma
associated with lung non-small cell carcinoma

RGD

PMID:20132185 PMID:26265454 PMID:24097870

RGD:126779607, RGD:11532507, RGD:126781716

NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362

G

ezrin

CTD Direct Evidence: marker/mechanism

NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505

G

coagulation factor II, thrombin

associated with Carcinoma, Small cell;protein:increased expression:brain

RGD

NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486

G

Fas associated via death domain

CTD Direct Evidence: marker/mechanism

NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653

G

Fas cell surface death receptor

associated with Breast Neoplasms;protein:decreased expression:breast
associated with Mammary Neoplasms;protein:decreased expression:lung

RGD

PMID:17352235 PMID:17918178

RGD:2290053, RGD:2290048

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

associated with Breast Neoplasms;protein:decreased expression:breast

RGD

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fibroblast growth factor 13

CTD Direct Evidence: marker/mechanism

NCBI chr X:137,276,498...137,800,056
Ensembl chr X:137,276,511...137,800,391

G

Fibroblast growth factor receptor 1

associated with prostate adenocarcinoma

RGD

NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350

G

Fms related receptor tyrosine kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

fibronectin 1

treatment

associated with stomach cancer; human cells in mouse model

RGD

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

fascin actin-bundling protein 1

associated with Pancreatic Neoplasms

RGD

NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211

G

ferritin light chain 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725

G

GRB2-associated binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:151,429,844...151,625,708
Ensembl chr 1:151,429,695...151,625,031

G

growth differentiation factor 15

CTD Direct Evidence: marker/mechanism

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

gap junction protein, beta 1

CTD Direct Evidence: marker/mechanism

NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925

G

glycoprotein Ib platelet subunit alpha

associated with Melanoma, Experimental

RGD

NCBI chr10:55,352,938...55,355,804
Ensembl chr10:55,352,899...55,356,774

G

glycerophosphocholine phosphodiesterase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:119,787,681...119,832,550
Ensembl chr 3:119,787,682...119,832,517

G

glucose-6-phosphate isomerase

RGD

NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086

G

glutathione peroxidase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

hyaluronan binding protein 2

treatment

associated with Thyroid Neoplasms

RGD

NCBI chr 1:255,315,870...255,350,161
Ensembl chr 1:255,315,915...255,350,160

G

hepatitis A virus cellular receptor 2

disease_progression

DNA:polymorphisms: : +4259T>G (human)

RGD

NCBI chr10:30,882,484...30,914,018
Ensembl chr10:30,882,606...30,909,137

G

histone deacetylase 3

associated with Anaphylaxis;
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:34973135 PMID:24619412

NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856

G

hepatocyte growth factor

associated with Pancreatic Neoplasms
CTD Direct Evidence: marker/mechanism
associated with Mammary Neoplasms, Experimental;
associated with Melanoma;

CTD
RGD

PMID:25971889 PMID:11893931 PMID:16459153 PMID:10688652

RGD:2317904, RGD:8548625, RGD:8548538

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

heparanase

CTD Direct Evidence: marker/mechanism

NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010

G

histamine receptor H 2

CTD Direct Evidence: marker/mechanism

NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631

G

heat shock protein 90 alpha family class A member 1

CTD Direct Evidence: marker/mechanism

NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268

G

heat shock protein family A (Hsp70) member 1A

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

integrin-binding sialoprotein

CTD Direct Evidence: marker/mechanism

PMID:22407340 PMID:24980816

NCBI chr14:5,439,825...5,452,570
Ensembl chr14:5,439,829...5,452,693

G

intercellular adhesion molecule 1

associated with Pancreatic Neoplasms;protein:increased expression:serum
associated with Melanoma, Cutaneous Malignant

RGD

PMID:12923961 PMID:10465581

RGD:2325163, RGD:8547593

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

inhibitor of DNA binding 1

CTD Direct Evidence: therapeutic

NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419

G

insulin-like growth factor 1

associated with Pancreatic Neoplasms
CTD Direct Evidence: marker/mechanism
associated with Uveal Melanoma;protein:increased expression:serum:

CTD
RGD

PMID:18398872 PMID:19375852 PMID:23197685

RGD:2317643, RGD:8548834

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor 1 receptor

associated with Pancreatic Neoplasms

RGD

NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777

G

insulin-like growth factor 2

associated with Arthritis, Experimental; protein:increased expression:lung, bone, serum:

RGD

NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018

G

IKAROS family zinc finger 1

associated with colorectal cancer;DNA:polymorphisms:

RGD

NCBI chr14:86,255,065...86,340,839
Ensembl chr14:86,255,065...86,342,416

G

interleukin 10

RGD

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 18

protein:increased expression:serum
CTD Direct Evidence: marker/mechanism
associated with breast cancer;DNA:SNP:promoter:-137G>C (rs187238) (human)
associated with breast cancer;protein:increased expression:serum

CTD
RGD

PMID:12748951 PMID:11215816 PMID:19152241 PMID:12209760

RGD:4889862, RGD:8655899, RGD:8655866

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 2

treatment

associated with melanoma;
associated with neuroblastoma.
CTD Direct Evidence: therapeutic

CTD
RGD

PMID:17105418 PMID:8610104 PMID:9362156 PMID:8642346

RGD:8663438, RGD:14865005, RGD:14747043

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 6

treatment

associated with stomach cancer, human cells in mouse model
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:21937440 PMID:26101800 PMID:28186964

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit alpha 6

RGD

NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428

G

integrin subunit beta 1

CTD Direct Evidence: marker/mechanism

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

integrin subunit beta 3

mRNA, protein:increased expression:lung
associated with renal cell carcinoma;DNA:missense mutation:cds:p.L33P (human)

RGD

PMID:21107114 PMID:16831169

RGD:5037225, RGD:6907406

NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679

G

Janus kinase 2

treatment

associated with stomach cancer, human cells in mouse model

RGD

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

junction plakoglobin

associated with Ovarian Neoplasms

RGD

NCBI chr10:85,300,438...85,327,378
Ensembl chr10:85,300,440...85,327,057

G

lysine demethylase 6A

disease_progression

associated with lung adenocarcinoma;protein:increased expression:brain (human)

RGD

NCBI chr X:4,337,466...4,477,100
Ensembl chr X:4,337,750...4,477,062

G

kinase insert domain receptor

associated with Carcinoma, Renal Cell

RGD

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

kinesin family member 2C

disease_progression

associated with colorectal cancer

RGD

NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637

G

KiSS-1 metastasis-suppressor

associated with Ovarian Neoplasms

RGD

NCBI chr13:44,775,106...44,780,707
Ensembl chr13:44,774,823...44,780,612

G

lysine methyltransferase 2B

associated with lung adenocarcinoma

RGD

NCBI chr 1:85,821,700...85,840,987
Ensembl chr 1:85,821,753...85,841,326

G

lysine methyltransferase 2D

disease_progression

associated with colorectal cancer;DNA:mutations::

RGD

NCBI chr 7:129,980,744...130,022,088
Ensembl chr 7:129,962,887...130,020,325

G

KRAS proto-oncogene, GTPase

treatment
disease_progression

CTD Direct Evidence: marker/mechanism
associated with stomach cancer; human cells in mouse model
associated with colorectal cancer; DNA:mutation:cds:
associated with colorectal cancer;DNA:mutations: :
associated with colorectal cancer;DNA:mutation: :
associated with Fibrosarcoma;mRNA,protein:decreased expression::

CTD
RGD

PMID:8635384 PMID:27431311 PMID:27264476 PMID:26210240 PMID:29032374 More...

RGD:152995400, RGD:14398751, RGD:11086960, RGD:14398745, RGD:11570402

NCBI chr 4:178,185,418...178,218,484

G

keratin 14

mRNA:decreased expression:epithelial cell

RGD

NCBI chr10:85,137,786...85,142,054
Ensembl chr10:85,066,802...85,171,799

G

keratin 20

associated with Colorectal Neoplasms

RGD

NCBI chr10:84,384,790...84,394,125
Ensembl chr10:84,384,802...84,394,107

G

L1 cell adhesion molecule

treatment

associated with Pancreatic Neoplasms;
associated with Lung Neoplasms;

RGD

PMID:22095073 PMID:22307136

RGD:11570404, RGD:11570503

NCBI chr X:151,597,270...151,623,776
Ensembl chr X:151,597,277...151,623,857

G

laminin subunit gamma 2

associated with lung adenocarcinoma;

RGD

NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200

G

lipocalin 2

CTD Direct Evidence: marker/mechanism

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

leukocyte cell-derived chemotaxin 2

CTD Direct Evidence: therapeutic

NCBI chr17:8,044,759...8,050,983
Ensembl chr17:8,044,759...8,050,983

G

lymphoid enhancer binding factor 1

associated with prostate cancer
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:27811057 PMID:27067790

NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794

G

galectin 3

CTD Direct Evidence: marker/mechanism

NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025

G

LLGL scribble cell polarity complex component 2

CTD Direct Evidence: marker/mechanism

NCBI chr10:101,050,978...101,086,527
Ensembl chr10:101,051,408...101,086,525

G

lymphocyte antigen 96

CTD Direct Evidence: marker/mechanism

NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386

G

MET transcriptional regulator MACC1

treatment

associated with stomach cancer; human cells in mouse model
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:36008464 PMID:27431311

NCBI chr 6:140,352,690...140,430,255
Ensembl chr 6:140,352,755...140,430,255

G

mitogen activated protein kinase kinase 4

disease_progression

associated with oral squamous cell carcinoma;mRNA, protein:increased expression:lymph node (human)

RGD

NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993

G

mitogen activated protein kinase 1

treatment

CTD Direct Evidence: marker/mechanism
associated with prostate adenocarcinoma

CTD
RGD

PMID:22580338 PMID:22139534

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

CTD Direct Evidence: marker/mechanism

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 9

CTD Direct Evidence: therapeutic
associated with Colorectal Neoplasms

CTD
RGD

PMID:21779479 PMID:25205654

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

mediator complex subunit 28

CTD Direct Evidence: marker/mechanism

NCBI chr14:65,594,785...65,603,583
Ensembl chr14:65,594,647...65,603,583

G

MET proto-oncogene, receptor tyrosine kinase

disease_progression

associated with Squamous Cell Carcinoma of the Tongue;
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20080979 PMID:21225626 PMID:22704061

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

microRNA 100

CTD Direct Evidence: marker/mechanism

NCBI chr 8:41,901,225...41,901,304
Ensembl chr 8:41,901,225...41,901,304

G

microRNA 106a

CTD Direct Evidence: marker/mechanism

NCBI chr X:132,422,584...132,422,661
Ensembl chr X:132,422,584...132,422,661

G

microRNA 125a

CTD Direct Evidence: marker/mechanism
associated with stomach cancer;

CTD
RGD

PMID:19487542 PMID:30117667

NCBI chr 1:58,677,626...58,677,710
Ensembl chr 1:58,677,626...58,677,710

G

microRNA 130a

CTD Direct Evidence: marker/mechanism

NCBI chr 3:69,822,542...69,822,629
Ensembl chr 3:69,822,542...69,822,629

G

microRNA 130b

CTD Direct Evidence: marker/mechanism

NCBI chr11:83,880,163...83,880,244
Ensembl chr11:83,880,163...83,880,244

G

microRNA 136

ameliorates

associated with stomach cancer;human cells in mouse model

RGD

NCBI chr 6:128,549,096...128,549,177
Ensembl chr 6:128,549,096...128,549,177

G

microRNA 148b

CTD Direct Evidence: marker/mechanism

NCBI chr 7:134,421,398...134,421,494
Ensembl chr 7:134,421,398...134,421,494

G

microRNA 152

associated with Castration-Resistant Prostatic Neoplasms

RGD

NCBI chr10:81,832,936...81,833,020
Ensembl chr10:81,832,936...81,833,020

G

microRNA 155

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:19487542 PMID:27692344 PMID:27856635

NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718

G

microRNA 181c

CTD Direct Evidence: marker/mechanism

NCBI chr19:23,983,523...23,983,628
Ensembl chr19:23,983,523...23,983,628

G

microRNA 181d

CTD Direct Evidence: marker/mechanism

NCBI chr19:23,983,706...23,983,788
Ensembl chr19:23,983,706...23,983,788

G

microRNA 193a

exacerbates

associated with lung non-small cell carcinoma; human cells in mouse model

RGD

PMID:24469061 PMID:30685413

RGD:153344592, RGD:153344599

NCBI chr10:64,672,343...64,672,454
Ensembl chr10:64,672,343...64,672,454

G

microRNA 19a

CTD Direct Evidence: marker/mechanism

NCBI chr15:92,180,912...92,180,993
Ensembl chr15:92,180,912...92,180,993

G

microRNA 205

CTD Direct Evidence: marker/mechanism

NCBI chr13:105,035,878...105,035,985
Ensembl chr13:105,035,878...105,035,985

G

microRNA 20a

associated with colorectal cancer

RGD

NCBI chr15:92,181,084...92,181,168
Ensembl chr15:92,181,084...92,181,168

G

microRNA 20b

CTD Direct Evidence: marker/mechanism

NCBI chr X:132,422,211...132,422,282
Ensembl chr X:132,422,211...132,422,282

G

microRNA 21

treatment
ameliorates

associated with prostate carcinoma; human cells in mouse model
CTD Direct Evidence: marker/mechanism
human cells in mouse model;associated with breast cancer

CTD
RGD

PMID:26101800 PMID:32736696 PMID:18270520

RGD:152998873, RGD:152998897

NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348

G

microRNA 221

CTD Direct Evidence: marker/mechanism

NCBI chr X:3,429,465...3,429,573
Ensembl chr X:3,429,465...3,429,573

G

microRNA 222

CTD Direct Evidence: marker/mechanism

NCBI chr X:3,428,904...3,429,006
Ensembl chr X:3,428,904...3,429,006

G

microRNA 224

CTD Direct Evidence: marker/mechanism
associated with colorectal cancer; mRNA:increased expression:colorectal mucosa:

CTD
RGD

PMID:19487542 PMID:25919696

NCBI chr X:150,065,088...150,065,169
Ensembl chr X:150,065,088...150,065,169

G

microRNA 30a

CTD Direct Evidence: marker/mechanism

NCBI chr 9:25,737,600...25,737,670
Ensembl chr 9:25,737,600...25,737,670

G

microRNA 30e

CTD Direct Evidence: marker/mechanism

NCBI chr 5:134,352,232...134,352,323
Ensembl chr 5:134,352,232...134,352,323

G

microRNA 31

disease_progression
treatment

CTD Direct Evidence: marker/mechanism
associated with colorectal cancer;RNA:increased expression:colorectum (human)
associated with stomach cancer;human cells in mouse model

PMID:19487542 PMID:26497852 PMID:27174918 PMID:30108104

RGD:153297806, RGD:153297811, RGD:153297776

NCBI chr 5:103,599,038...103,599,143

G

microRNA 342

CTD Direct Evidence: marker/mechanism

NCBI chr 6:127,565,269...127,565,367
Ensembl chr 6:127,565,269...127,565,367

G

microRNA 346

CTD Direct Evidence: marker/mechanism

PMID:27501413 PMID:27777383

NCBI chr16:10,218,118...10,218,215
Ensembl chr16:10,218,118...10,218,215

G

microRNA 34b

CTD Direct Evidence: marker/mechanism

NCBI chr 8:51,410,244...51,410,327
Ensembl chr 8:51,410,244...51,410,327

G

microRNA 34c

CTD Direct Evidence: marker/mechanism

NCBI chr 8:51,409,726...51,409,802
Ensembl chr 8:51,409,726...51,409,802

G

microRNA 370

CTD Direct Evidence: marker/mechanism

NCBI chr 6:128,572,257...128,572,335
Ensembl chr 6:128,572,257...128,572,335

G

microRNA 494

associated with osteosarcoma; RNA:decreased expression:bone, serum

RGD

PMID:30314946 PMID:35117781

RGD:156420141, RGD:156430319

NCBI chr 6:128,728,710...128,728,792
Ensembl chr 6:128,728,709...128,728,793

G

microRNA 503

CTD Direct Evidence: marker/mechanism

NCBI chr X:132,806,303...132,806,373
Ensembl chr X:132,806,303...132,806,373

G

microRNA 532

CTD Direct Evidence: marker/mechanism

NCBI chr X:15,247,315...15,247,393
Ensembl chr X:15,247,315...15,247,393

G

microRNA 96

CTD Direct Evidence: marker/mechanism

NCBI chr 4:58,788,411...58,788,516
Ensembl chr 4:58,788,411...58,788,516

G

microRNA 99a

CTD Direct Evidence: marker/mechanism

NCBI chr11:16,200,443...16,200,523
Ensembl chr11:16,200,443...16,200,523

G

microRNA 99b

CTD Direct Evidence: marker/mechanism

NCBI chr 1:58,677,015...58,677,084
Ensembl chr 1:58,677,011...58,677,090

G

marker of proliferation Ki-67

associated with Pancreatic Neoplasms

RGD

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

mutL homolog 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617

G

matrix metallopeptidase 1

CTD Direct Evidence: marker/mechanism